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Abstract 
Microfluidics manipulates, processes, and controls small volumes of fluids in 
channels or compartments with cross-sectional dimensions on the order of 10-100 µm. 
By integrating functional components such as channels, actuators, and sensors, and by 
leveraging characteristic physical phenomena occurring at the microscale, microfluidics 
brings microfabrication, chemistry and physics together to develop new experimental 
paradigm for broad applications, including the study of biological problems.  Indeed, 
microfluidics operates at a scale that is particularly suitable for biological sample analysis, 
which provides great opportunities for technology innovation in bioanalytical assays and 
biomedical applications such as point-of-care devices.  Challenges due to the complexity 
of the biological system can be overcome by introducing new engineering elements and 
performing systematic device optimization.  In this work, a microfluidic immunoaffinity 
based silicon micropost device for hematopoietic stem cell enrichment is discussed, 
which demonstrates how innovations in microfluidics can revolutionize current clinical 
therapies.  Appropriate surface chemistry for robust immobilization of proteins on the 
surface of different materials and topography was developed.  Silicon chips with three-
dimensional features, arrays of microposts in a wide range of arrangements, were 
designed. The fluid dynamics in the various micropost arrays was modeled and optimized 
to meet specific needs of cell enrichment for clinical application. The optimized three-
dimensional micropost devices achieve hematopoietic stem cell enrichment at a level that 
outperforms all current technologies and successfully meets the requirements for clinical 
transplantation applications.  
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CHAPTER 1  
INTRODUCTION 
 
1.1 Overview of the Dissertation 
Stem cells have been a focus of research due to their great promise for the 
development of new treatments for human diseases such as Parkinson's disease, 
diabetes, and various types of cancer [1-4]. Motivated by this promise, enormous 
efforts have been made ranging from identification and enrichment of stem cells, to 
understanding their underlying biology. Hematopoietic stem cells (HSCs) are adult 
stem cells found in bone marrow. They give rise to all different blood cell types.  
Significant progress has been achieved in identification and enrichment of HSCs in 
recent years [5-7]. For example, CD34 and other lineage markers have been 
discovered for the recognition of HSCs in blood and techniques have been developed 
to enrich HSCs for blood transplantation [8-11]. The current understanding in the 
biology of HSCs as well as the technologies have been developed to identify and 
isolate HSCs are discussed in detail in Chapter 2.  
However, current enrichment techniques have limitations such as low purity, low 
throughput, and poor reproducibility in yield. The first part of my Ph.D. work aims to 
develop a new microfluidic platform to enrich HSCs with high purity, high capture 
efficiency, and high throughput. After identifying suitable operational parameters by 
studying cell-surface affinity under a range of flow and shear stress conditions in 
Chapter 3, Chapter 4 reports the design and preliminary validation of the microfluidic 
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cell enrichment platform. Subsequently, HSC enrichment was achieved at a high 
capture efficiency up to 87% and a high purity up to 80% at a throughput of 5 × 103 
cells/s in the current testing device (Chapter 5), which could be easily enhanced to 105 
cells/s by further modifications to the device.  
Besides the identification and enrichment of HSCs, many growth factors and 
environmental factors have been identified in regulating HSC proliferation and 
differentiation. However, the interactions between HSCs and their various 
microenvironments are still not fully understood.  The mystery mechanism for the 
maintenance of HSCs in their lifespan starting from a hypoxia environment in bone 
marrow and eventually migrating to a normoxia environment in peripheral blood is 
significant in understanding stem cell biology as well as developing therapeutic 
strategies for HSC transplantation [5, 12-14]. Increased oxygen tension leads to 
elevated level of reactive oxygen species, which are involved in many cellular 
processes, including regulation of proliferation and differentiation, activation of 
signaling pathways, apoptosis, aging, etc [15-17]. In order to survive from the 
potential oxidative stresses as a result of the increased oxygen tension in the 
environment, antioxidant may be present on the HSCs to fight against the oxidative 
stresses. The second part of my work is to investigate the biological roles of CD34 in 
HSCs beyond a simple marker. Our hypothesis is that CD34 has the potential to act as 
a free radical scavenger to help maintain the “stemness” of HSCs under increasing 
oxidative stress [15-17]. Preliminary data indicated that CD34 did have the potential 
to protect cells from apoptosis induced by hydrogen peroxide (Chapter 6). This study 
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will examine a possible novel function for a long-studied, but poorly understood cell 
surface marker of HSCs and improve capabilities for preserving and expanding HSCs 
in vitro.  
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CHAPTER 2  
LITERATURE REVIEW:  
MICROFLUIDIC DEVICE FOR HSC ENRICHMENT 
 
2.1 The Biology of Hematopoietic Stem Cells 
Stem cells are the natural units of embryonic generation and adult regeneration of 
tissues. They are in undifferentiated state, and exhibit both self-renewal and 
multilineage differentiation capabilities. Hematopoietic stem cells are those cells that 
can sustain the production of blood cells of all hematopoietic lineages and are capable 
of generating daughter stem cells with similar pluripotent properties, as shown in 
Figure 2.1. HSCs are mostly found within the bone marrow at a very low percentage 
(typically 0.1-5% after white blood cells are removed). They can also circulate into 
the peripheral blood, at even lower percentage (less than 0.01%) [1]. Other sources of 
HSCs include umbilical cord blood and fetal liver. Since Till and McCulloch provided 
the first direct evidence of the presence of pluripotential hematopoietic cells with self 
renewal capacity in mouse bone marrow in 1961 [2], broad understanding in the 
molecular processes regulating cell growth and differentiation of HSCs have been 
achieved. Clinical therapy is developed based on current knowledge of HSC biology 
and is now routinely used to treat patients with cancers and other disorders of the 
blood and immune systems. Furthermore, in some recent animal studies, HSCs have 
been observed to form non-hematopoietic cell types, such as blood vessels, muscle, 
and bone, which make them more versatile for potential applications in regenerative 
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medicine [3]. Despite the advances in biology and clinical therapy, hematopoietic 
system also poses considerable challenges and thus opportunities. First, no unique and 
stable phenotype has been identified to recognize HSCs and progenitor cells. Second, 
proliferation and differentiate of HSCs in vitro are not easy. Third, the abundance of 
HSCs and progenitor cells in hematopoietic tissues are extremely low. Thus future 
studies of HSC rely on the development of cell separation techniques for highly pure 
populations of primitive hematopoietic cells. 
2.2 Hematopoietic Stem Cell Transplantation 
The capability of repairing or replacing damaged tissues and organs has been 
pursued for centuries. Cell therapies based on hematopoietic stem cells have become 
the standard of treatment for a variety of blood and immune diseases especially 
leukemia and lymphoma [4]. Bone marrow transplantation, peripheral blood stem cell 
transplantation and cord blood stem cell transplantation are the common types of 
HSCTs. In a typical HSCT, patients are given high doses of chemotherapy or radiation 
therapy, which kills cancer cells and destroys significant amount of if not all the 
normal cells developing in the bone marrow, including the stem cells [5]. Then a 
healthy supply of stem cells is transplanted to reconstitute the blood cell process in the 
bone marrow. Depending on the types of cancers, patient disease status, and the 
sources of the HSCs for transplantation, transplantation therapy and strategies vary 
significantly. Consequently, the successfulness and potential issues related to each 
specific HSCT are less predictable. Major concerns include, first, the necessity of 
introducing purging or other cell sorting process to get rid of the cancer cells or some 
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white blood cells which are known for their strong immune interference with certain 
types of cancer treatment; second, relapse, which is the reemission of cancer cells 
differentiated from cancer stem cells that survive from the therapy due to insufficient 
dose of drug or radiation; and third, the rejection caused by the immune system such 
as graft vs. host diseases in allogeneic transplantation [6]. All of above concerns are 
related to the complicated and highly heterogeneous subpopulations of white blood 
cells from the patients. To increase the precision of target cell recognition and the 
sophistication of the clinical therapies, we need further understanding of the biology 
of HSCs, which again relies on the ability to purify functionally homogeneous 
population of HSCs as well as other important immune functional white blood cells. 
Only if the purification technology improves and further knowledge on HSC biology 
advances, it will become possible to establish “cocktail” receipt to selectively choose 
subpopulations of blood cells according to the specifics of the patient conditions and 
even to customize the choice of stem cells and progenitor cells for genetic 
modification based on the specifics of individual therapies.   
2.3 Phenotypic Characteristics of Hematopoietic Stem Cells 
A large number of cell surface antigens or characteristic proteins for different 
subpopulations of hematopoietic cells have been revealed using functional assays, 
however, no unique and stable phenotype has been identified for HSCs. Markers that 
are identified for rare populations that are highly enriched for stem cells are either 
identified from colony forming cells (CFC), competitive repopulating units (CRU) or 
from long term culture initiating cells (LTCIC) [7]. Some markers are associated with 
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the quiescent status of the majority of stem cells in the healthy adults. Others are 
based on the fact that many antigens expressed on the surface of mature blood cells 
are not expressed on the primitive ones or vice versa. However, most markers are not 
reliable enough for the isolation of the stem cell populations, since the current 
understandings of the correlations between markers and subpopulations are not clearly 
maintained in normal and perturbed hematopoiesis [8]. 
The mostly used monoclonal antibodies for isolating primitive human 
hematopoietic cells react with CD34, which a heavily glycosylated transmembrane 
protein expressed on 0.1–5% of normal adult human bone marrow cells and bone 
marrow mobilized peripheral blood. Most CD34 positive cells do not express many of 
lineage markers, which are the surface markers expressed on terminally differentiated 
hematopoietic cells. The isolation of CD34 positive cells from normal human bone 
marrow or mobilized blood yields populations that contain high CFC, LTC-IC, and 
CRU content, although these populations are still very heterogeneous phenotypically 
and functionally. In one study, approximately 10% of isolated CD34 positive cells 
have in vitro colony-forming potential of which, 10% of these will form multilineage 
colonies [8]. A few additional cell surface markers have proven useful in further 
dividing the CD34 positive population into more functionally homogeneous 
populations. Thy-1 and AC133 are two antigens that found to be selectively expressed 
on primitive human hematopoietic progenitors. Thy-1 is expressed on approximately 
25% of CD34 positive cells in human fetal liver, cord blood, and bone marrow and on 
a majority of LTC-IC, but not on a majority of the CD34 positive CFC [9]. AC133, on 
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the other hand, is expressed on 20–60% of CD34 positive cells, including LTC-IC, but 
not on all the CFC [10]. However, despite all the uncertainties and controversies in 
the phenotypic characteristics of HSCs, CD34 is still the main marker people use to 
identify primitive hematopoietic cells.  
2.4 Current Technology for Hematopoietic Stem Cell Purification  
Cell separation can be achieved by selectively physical removal or selective 
killing of cells from a mixed suspension. Techniques have been developed based on 
the differences in cell size or density, sensitivity to pharmacologic agents, or cell 
surface phenotype. Enriched or depleted cells can be characterized by their 
phenotypic, biochemical, or functional properties.  
2.4.1 Cell separation based on size and density 
Depending on the density of the medium as well as the size and density of the cell, 
cells moves at different rates in medium when a centrifugal force is applied. Since 
mature blood cells vary in both size and density, different subsets of blood cells such 
as the denser erythrocytes, the intermediate granulocytes and neutrophils, and the 
lighter lymphocytes and monocytes can be separated by centrifugation when the 
density of the medium is properly designed [11]. Counterflow elutriation can be used 
as an additional separation force in the opposite direction of the centrifugal force, thus 
enabling further extraction of lymphocyte fraction, where HSCs are found 
predominantly in, from the remaining monocytes [12-13]. This approach is most 
effective in removing normal mature red cells from whole blood but much less 
effective in separating different types of leukocytes, especially for rare cell separation 
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such as HSC purification since it is very subject to the sample conditions and 
dependent largely on the abundance of other cell types in the sample.  
2.4.2 Cell separation by using selective cell killing agents 
The slow turnover of hematopoietic stem cells in normal adult bone marrow 
makes the majority of them insensitive to short-term exposure to agents that kill 
cycling but not quiescent cells. 4-Hydroperoxycyclophosphamide and mafosfamide 
are examples of pharmacologic agents that have been used to purge cycling malignant 
cells from clinical blood and bone marrow autografts prior to their reinfusion [14-15]. 
Such treatments also eliminate most proliferating progenitor cells but not all the 
mature blood cells that are not cycling. Prolonged in vitro exposure to 5-fluorouracil 
has also been described for obtaining enriched populations of primitive human 
hematopoietic cells [16-17]. However, these strategies again only provide several fold 
of enrichment of HSCs from original sample, but by no means offer the potential to 
obtain a highly purified HSC population.  
2.4.3 Cell separation based on monoclonal antibodies 
The specificity and diversity of monoclonal antibodies offer enormous 
possibilities for separating distinct subsets of cells by using appropriate combinations 
of antibodies. Antibodies have been coupled to toxins for selective cell killing, to 
fluorochromes for fluorescent activated cell sorting (FACS as shown in Figure 
2.2A) [18], and to solid matrices (also known as immunoadsorption) for selective cell 
adherence to flasks, columns of beads, and magnetic particles. Depending on the 
sample conditions and enrichment requirements, both positive selection and negative 
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selection are being used. Positive selection is targeting the cells of interests with 
specific antibody conjugations and the remaining unlabeled cells are removed. 
Negative selection, on the other hand, is selecting the unwanted cells with antibodies 
and the remaining unselected target cells are collected. FACS as well as the 
immunoadsorption techniques can be tailored for either positive or negative selection 
applications. FACS and magnetic activated cell sorting (MACS, Figure 2.2 B) based 
on antibody conjugated magnetic particles are the two most commonly used technique 
in clinical and research applications nowadays [19]. FACS offers very high purity of 
the enriched population since it is a single cell analysis where each cell goes through a 
laser beam one by one for the detection of the presence of fluorescence on the cell as 
a result of target antigen-antibody interactions [20]. However, the throughput (103 
cells/s) that can be achieved with FACS is limited because its principle is based on 
analyzing one cell at a time. FACS is not capable of processing very large numbers of 
cells (more than 109 cells) in a timely fashion as required for clinical and research 
applications. Immunoadsorption technique, however, have proven to be very 
attractive for both clinical and research applications because they are based on parallel 
analysis that can be easily scaled up to deal with the large numbers of cells present in 
clinical transplants. MACS, in particular, is widely accepted on the market due to the 
high throughput it provides. However, MACS doesn’t guarantee a reproducible high 
purity as that in FACS since again the separation is not operating on single cell level. 
Since FACS and MACS offer complementary performance, they have been used in 
multistep enrichment strategies to obtain highly purified large number of cells within 
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a short time frame. MACS is often used in an earlier step to pre-enrich the population 
while FACS has been used as the last step of positive selection to achieve high purity 
of the population. The combination of FACS and MACS seems to provide a solution 
to high purity and high throughput HSC purification. However, multi-step separation 
significantly increases the overall processing time and overall cell losses.  
The more difficult a cell type is to identify, and the rarer it is, the greater the 
challenge for its purification. As a result, even though much has been learned about 
the unique features of HSCs, the efforts to develop simpler, faster and more reliable 
separation strategies continue since many questions about stem cell biology and 
further progresses in clinical stem cell transplantation therapies require the use of 
larger numbers of highly enriched cell suspensions than have been generally available 
on a routine basis.    
2.5 Microfluidics in Biomedical Applications 
2.5.1 Microfluidics  
Microfluidic technology has been developed since early 1980s [21].  The 
miniaturized systems can be used to realize protocols that are performed at the 
traditional laboratory scale (ml to l) with advantages of a smaller size, less reaction 
time, less sample consumption, reduced risk of contamination, higher sensitivity, 
higher reliability, and the ability to run multiple processes sequentially or in parallel in 
an integrated system [22]. By integrating functional components such as channels, 
actuators and sensors, and leveraging characteristic physical phenomena in microscale, 
microfluidics brings microfabrication, chemistry and physics together to develop new 
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experimental paradigm for broad applications in numerous fields.  
A material effect of reactor miniaturization is that fluid properties become 
increasingly controlled by viscous forces rather than inertial forces [23]. This 
relationship can be understood through use of the dimensionless Reynolds number 
(Re), 
 
Here ρ is the density of the fluid, η the viscosity of the fluid, ν the characteristic 
velocity and lc is the characteristic length. Reynolds numbers in microfluidics are 
small (less than 1) as a result of the small length scale, indicating that flow is laminar 
in contrast to 103 or higher in macroscale, where flow regimes are almost always 
turbulent. The characteristics of laminar flow regimes is that fluid follows streamlines 
that are constant with time and do not overlap to induce conventional mixing. Since 
the length scales in microfluidic structures are small, diffusion times can be extremely 
short. Accordingly, diffusion aids mass transport for flows in microdevices. As a result, 
fluid behavior is highly repeatable and controllable for precise reaction operation and 
reagent control. In addition, the high surface area to volume ratios is another 
advantage of microscale environments, which indicates a significant proportion of the 
fluid will be in contact with the microchannel surface during transit and thus the 
reaction efficiency at the interface is highly enhanced. Another key feature of 
continuous flow in microscale is the parabolic pattern of pressure-driven laminar 
flows, where the distribution of local velocity determines the progression of chemical 
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reactions, which again can be taken advantages to design local features for specific 
applications.  
System integration is another exciting aspect of microfluidic systems. The 
incorporation of multiple basic components, such as valves, mixers, pumps, sensors, 
and distinct functional components, such as memory, comparators, counters, and 
multiplexers, on a single chip with the size of a post stamp to perform sample 
purification, labeling, detection and separation together has been achieved in many 
designs and applications [24]. The numerous components enable an unlimited set of 
tools for automation, which provides great promise to replace many conventional 
technologies and enable novel technologies to be developed to perform new tasks and 
overcome current challenges.  
Since microfluidics operates at the scale particularly suitable for biological 
sample analysis, it provides great opportunities for technology innovation in 
bioanalytical assays and biomedical applications such as point-of-care devices [25-26]. 
Challenges due to the complexity of the biological system can be overcome by 
introducing new engineering elements and performing systematic device optimization. 
The miniaturized systems offer tremendous advantages, such as smaller size, less 
reaction time, less sample consumption, reduced risk of contamination, higher 
sensitivity and reliability, precise control of the flow behavior, and the ability to run 
multiple processes sequentially or in parallel in an integrated system. In addition, 
microfluidics offers affordable analysis and procedures without the need of well 
equipped, expensive laboratories and skilled technicians often in combination with 
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more gentle protocols that are less likely to alter the native states of the sample [27].  
Microfluidics also provides great versatility and flexibility in that these devices can be 
tailored for specific applications. This often helps in overcoming complicated and 
specific challenges presented by biological systems.  
2.5.2 Microfluidics for cell separation 
Similar to the separation principles, the use of physical fields for the separation of 
cells takes advantage of the heterogeneity of physical properties of the blood cells. 
After exposure to fields of different nature (optical forces [28-29], dielectrophoretic 
forces [30], electrokinetic forces [31], magnetic fields [32], acoustic fields [33], 
gravity, hydrodynamic forces [34-35], and mechanical forces [36-37]), differences in 
basic physical properties such as size, deformability, electrical permittivity and 
dielectric characteristics, and differences in affinity such as adhesiveness based on 
various cell-cell interaction and cell-protein interactions can be revealed and used as 
basic principle for separation. Different from the traditional separation strategies, 
lab-on-a-chip technology takes advantages of the flexibility in device fabrication to 
add additional degrees of freedom in device design, in terms of channel geometry and 
three dimensional features, to explore and precisely control the differentiated 
interactions between the cell and the device under specific physical fields. 
Microfluidic cell separation techniques can be classified as active and passive 
separation techniques. Active separation requires external forces, such as optical, 
magnetic, dielectrophoretic and acoustic forces, for revealing differences between 
different populations, while passive techniques takes advantage of the channel 
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geometry, inertial forces, hydrodynamic forces and affinity for cell separation. 
2.5.2.1 Active separation techniques 
FACS and MACS are the dominating conventional technology in cell isolation 
that providing decent purity and throughput. On-Chip FACS and On-Chip MACS 
were also developed (Figure 2.3).  
Recent advances in microscale implementation of optics and flow control 
structures, have led to the development of different microsystems for cell separation 
comparable to the FACS sorting instruments. Optical identification has been 
combined with hydrodynamic liquid pumping and electrokinetic switching to 
demonstrate the separation of fluorescent labeled cells. The sample is focused 
hydrodynamically and the selection of particles is achieved through electroosmotic 
current flow by switching the fluid stream to one or another channel at the 
downstream junction. Optical forces [28], electrokinetic focusing and switching [38] 
and hydrostatic pressure [39]changes can be used to deflect the cells into different 
directions. Microfluidic cytometry eliminates the need to eject the cells in liquid 
droplets, which reduce cell viability. However, flow switching of On-Chip FACS 
requires much higher drag comparing droplet-based switching in conventional FACS. 
Droplet-based microfluidic FACS was designed to combine the advantages of 
traditional FACS and the benefits of microfluidics (Figure 2.3 A-C) [40-41].  
Immunomagnetic separations have also been extensively studied and are the 
principle behind numerous commercial products. Chaotic trajectories of the magnetic 
particles, generated through appropriate temporal variations of electric currents in 
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microconductors imbedded in microchannel walls, have been employed to enhance 
the mixing of particles and cells [42]. Ferrofluid-based capture reagents consisting of 
magnetic nanoparticles coated with antibodies have also been reported for 
cell-separation applications [43]. Cells tagged with magnetic beads, when flowing 
through the microchannel, can be either simply captured in precise locations inside 
the channel or separated on an array of magnetic wires (Figure 2.3 D,E)  [44-45]. 
Overall, the purity of the final product and efficiency of the separation steps can be 
improved by the use of microscale devices. However, current On-Chip FACS and 
MACS devices are still limited by their low throughput compared to their macroscale 
counterparts.  
Dielectrophoresis (DEP) uses the electrical polarization of cells in non-uniform 
electric fields to induce translational motion or reorientation of cells, affecting their 
dynamic behavior. Since the critical dimension of the induced electrical interactions is 
in microscale, DEP is particularly useful in microfluidics. Obstacles on microscale 
such as ridges and wedges embedded in the microchannel can be also used to generate 
heterogeneous electric field required for the DEP based cell sorting. Depending on the 
frequency and the conductivity of cell cytosol and surrounding medium, these forces 
tend to hold the cell in place near the high field region (positive dielectrophoresis) or 
push the cell away from the high field region (negative dielectrophoresis) (Figure 
2.4A) . The induced polarization depends on the frequency of the electrical field, the 
conductivity of cell cytosol and surrounding media. More specifically, the magnitude 
of the dielectrophoretic force is strongly dependent on size of the cell and determined 
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by membrane properties, including permeability, capacitance, and conductivity. Since 
the inherent electrical characteristics of cells are based on cell type and different 
activate state, DEP offers more specificity in recognizing target cells. Cell populations 
that have been separated include bacteria from blood  [46], one cell population from 
another [47], live from dead cells (Figure 2.4B,C) [48], and cultured cancer cells from 
normal cells [49]. Since DEP devices do not involve cell labeling or cell modification, 
they are very good for downstream analysis. However, DEP is still based on physical 
properties rather than functional related biological phenotypical characteristics. 
Natural cell size variations can override the cell-type specific differences in DEP 
recognition and DEP is strongly affected by the conductivity of medium. Therefore, 
the purity of the target population is not guaranteed. DEP is also limited by its 
throughput for clinical applications. 
In addition to the FACS, MACS and DEP, optical and acoustic forces have been 
developed for cell sorting. Light has been used to manipulate and separate particles 
depending on their optical polarizability or deformability (Figure 2.5A) [29]. 
Ultrasonic acoustic resonance induced by piezoelectric material, can produce 
radiation force to manipulate particles and molecules based on size and refractive 
index (Figure 2.5B) [50]. However, cell viability within the optical or radiation force 
field cannot be guaranteed in these techniques. Also the throughput of this technique 
is still limited compared with conventional techniques such as FACS.  
2.5.2.2 Passive separation techniques 
Comparing to the active separation techniques, which suffer from the impaired 
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viability of samples due to the external forces, additional on-chip components and 
fabrication, passive separation takes advantages of unique features and great 
flexibility and creativity in microfluidic designs and flow behavior, thus providing 
simple, and label free and external-force free separation with little alteration of cell 
functions and less chances of cell activation during separation.   
Novel and flexible channel geometries have been developed for size and 
deformability based cell sorting. Post and weir structures are two most popular three 
dimensional elements for this type of cell sorting. By tailoring spacing between the 
microposts, selection of cells based on their size and deformability can be achieved. 
For instance, a microfluidic device composed of slanted obstacles was developed for 
continuous blood cell separation between large and round leukocytes from small and 
biconcave discoid erythrocytes [51], and separation of large tumor cells from small 
normal blood cells [52]. In a more sophisticated array design, cells of a few 
micrometers differences in size were separated through differential lateral 
displacement owing to asymmetric bifurcation of laminar flow around obstacles with 
sizes comparable to the size of the particles (Figure 2.6A) [37]. This simple separation 
strategy offers continuously separation of cells over a wide range of particle sizes 
with superior resolution. By stacking up the micropost arrays of varying gaps, sorting 
of multiple sizes of cells in a single pass for the fractionation of whole blood was 
achieve. However, the presence of a large number of obstructions may lead to channel 
clogging issues. The weir design is also based on introducing three dimensional 
obstacles to achieve size based separation, but the design is less susceptible to channel 
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clogging. In the weir design, gaps are created in between weirs and the top cover. As 
a result, smaller cells are allowed to go through while larger cells are blocked (Figure 
2.6B) [53]. The weir design has been successfully proven in separating white blood 
cells from red blood cells as well as separating cancer cell lines from normal cells. 
However, both filtration systems that separate cells by geometrical differences would 
require variations in design for different samples and suffer from impaired size 
selectivity due to varied deformability of cells, which is responsible for the limited 
efficiency in target cell isolation.  
 Hydrodynamic properties and inertial lift forces inherent to cell motion in 
microfluidics have been manipulated using different microchannel design to develop 
size-based cell separation techniques. Pinched flow fractionation (PFF) is a novel 
hydrodynamic chromatographic technique for size-based separations. The sample 
stream is pumped along with a sheath buffer from two inlets to the microchannel 
consisting of a pinched segment, followed by a broadened segment with much larger 
width (Figure 2.7A) [54]. The cells are forced to align to one side of channel wall in 
the pinched segment where the smaller cells are aligned closer to the channel wall as 
compared to the bigger one. The differences in positions of cells in different sizes are 
amplifies in the broadened segment. Hydrodynamic filtration is another passive 
separation technique in a microfluidic device. In this technique, particle stream is 
pumped through a channel having multiple side branching outlets, which are used to 
align all particles along the walls of the microchannel by direct the liquid away from 
the main channel continuously (Figure 2.7B)  [35]. Again, the difference in size 
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determines that the smaller particles are pushed closer to the sidewall than larger 
particles, which allow them to be directed away the main channel earlier than the 
larger sized particles. Inertial lift forces including shear-induced lift force and the 
wall-induced lift force can be exploited to precisely manipulate the cell position 
within microchannel. Migration of cells in microchannels occurs due to the two 
inertial lift forces stops when two forces balance at the positions distinct for different 
cells (Figure 2.7C)  [55]. Since the above three techniques rely on hydrodynamic 
flow profile and inertial forces, the dimension of the channels can be comparably 
larger than the cell diameters, thus minimizing the chances of clogging and further 
increasing throughput. Furthermore, these cell separation principles can be easily 
integrated into other microfluidic modules due to their simple design and 
manipulation. However, these systems are only efficient in dilute samples, since the 
interaction between the cells largely influence the efficiency of this separation.  
Cell affinity based separation is another series of technology benefit from 
microfluidics. Similar as in FACS and MACS where the cells are separated based on 
their individual dynamic responses to the antibody, immunoaffinity based separation, 
immobilizing antibody or other marker specific ligand on the surface of the device 
instead of on fluorophore or magnetic beads as in the cases of FACS and MACS, also 
guarantees very high purity. In microchannels of size comparable to the cell diameter, 
cells can be effectively pushed closer to the antibody coated surfaces, facilitating 
interaction and capture. In addition, multiple cells are identified simultaneously and 
each cell is identified at multiple time points and locations as they go through the 
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device with cell specific markers coated on the surface, which provides high 
throughput and enrichment efficiency [56]. Selective capturing of circulating tumor 
cells from blood on micropost device covered with antibodies has been demonstrated 
(Figure 2.8) [57]. Besides immunoaffinity separation which is based on strong and 
specific antibody-antigen interactions, other weaker and less specific interactions can 
be used for affinity based cell separation in certain applications as well. Selective 
extraction of leukocytes from blood has been reported in microfluidic devices using a 
biomimetic approach, involving adhesive rolling of leukocytes from whole blood on 
selectin-coated surfaces [58]. Different nanostructured polymer surfaces with 
nanopillars, perpendicular and parallel nanolines have been demonstrated for label 
free separation and enrichment of human breast cancer cell lines based on adhesion 
differences of cells on different surface topographies [59]. Since the cells are captured 
on the surface of the device, the versatility in microfluidic design and fabrication for 
increasing surface area and the chances of interactions between cells and surface give 
great promise for high throughput performance. Affinity-based microfluidic 
separation strategies are promising as the next generation of cell sorting and isolation 
technology to provide specify and efficiency at the same time, leading to high purity 
and high throughput performance to enable many research and clinical applications.  
2.5.3 Microfluidics for HSC enrichment 
Blood cells respond and adapt to physiological changes dynamically. Several 
studies have reported that the exposure of blood cells to stimuli from the certain assay 
during the blood processing steps can alter their phenotypes [60-61]. The diversity of 
23 
 
white blood cells makes it more difficult to precisely identify target cells from whole 
blood. Gentle and precise extraction of HSCs without disturbing their original states is 
a big challenge. Furthermore, clinical HSC transplantation requires high 
selectivity/purity (greater than 80%) at or close to single cell level to overcome the 
challenges of identifying the rare HSCs from the heterogeneous white blood cells, 
high capture efficiency (greater than 80%) and high throughput (105 cells/ml) to 
process adequate number of cells for each transplantation before HSCs start to 
differentiate. Microfluidics not only offers precise control of the microenvironment, 
which allows ensuring gentle and proper manipulation of the target cells, but also 
provides the high reaction efficiency for high purity and high capture efficiency and 
the flexibility in design and fabrication to be tailored for high throughput.   
Many microfluidic devices with different separation principles taking advantage 
of physical and biological properties have been introduced. Physical based cell sorting 
methods are designed to separate cells based on their differences in physical 
properties such as size and deformability taking advantage of dielectrophoretic forces, 
inertial forces, and hydrodynamic forces  [33-34, 44, 62]. Since the resolution of 
separation is limited by the inherent variance of size and deformability of target cells, 
physical-based sorting techniques are usually not applicable in rare cell separation for 
clinical applications that requires high purity and high throughput. A microfluidic 
device using dielectrophoretic field-flow-fractionation (DEP-FFF) was reported to 
separate CD34+ HSCs from human breast cancer MDA-435 cells from a mixing ratio 
of 3:2 [63]. CD34 is a transmembrane protein expressed on HSCs, but not on any 
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mature blood cells. Cell separation was achieved by equilibrating cells at different 
heights in a fluid-flow profile under opposing DEP and gravitational forces. Although 
the technique provided very good selectivity (with a purity of 99.2%), HSC were 
separated from a cancer cell line instead of blood, and from an initial concentration of 
60% of the mixture, which is much greater than the frequency of HSC in blood. The 
throughput of the device was low (1 × 102 cells/s) as well. Another microfluidic 
device with integrated membrane for simultaneous valving and filtering was reported 
for HSC purification from bone marrow with an enrichment of up to 98% and a 
throughput of 10 cells/s (17.2 µl/min). This size-based filtration method provided high 
capture efficiency and purity, but the throughput was far from satisfactory. Biological 
based separations, based on the specific biological recognition of the target cells are 
more promising for large scale, rare cell separation, since biological recognition 
provides specificity and selectivity, and is not limited by channel geometry or 
dimension, which can be easy to scale up for high throughput. Differences in average 
rolling velocities between CD34 positive HSCs and CD34 negative cells on P-selectin 
coated surface was used to differentiate and sort HSCs with a purity of 28% and a 
throughput of 1.5 × 103 cells/ml  [64]. This method, based on the interactions 
between CD34 on HSCs and P-selectin was label free and required no pre- or post- 
processing steps. However, since the interactions between CD34 and P-selectin were 
not specific or strong, purity was not guaranteed. Similarly, an anti-CD34 
antibody-immobilized, cell-rolling column has been developed to separate CD34 
positive cells from CD34 negative cells by the CD34 density on cell surfaces, 
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however this method was only demonstrated to separate between two cell lines 
instead of actual HSCs [65]. A highly automated and integrated microfluidic system 
using magnetic-bead-based fluorescent immunoassay was demonstrated for isolation, 
counting, and sorting of HSCs from cord blood with a maximum purity of 88% and a 
throughput of 2 × 103 cells/ml [66]. The high purity benefits from the combination of 
FACS and MACS. However, the throughput was still limited by the drawbacks of 
FACS. All the HSC separation technology mentioned above have their distinct 
advantages. However, none of them met the requirements for high performance HSC 
enrichment that is characterized by high purity and high throughput to obtain 
sufficient number of homogeneous target cells within short period of time. New 
technology needs to be developed to improve the current state of art in HSC 
enrichment.  
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2.6 Figures  
 
Figure 2.1 The hematopoietic lineages of differentiation. The curved arrow indicates 
self-renewing ability. Two main lineages stem from hematopoietic stem cells (HSCs), 
originated from either myeloid or lymphoid progenitors, which in turn give rise to 
all blood and lymphatic cell types, respectively [67], copyright 2003, Elsevier. 
  
 
 
Figure 2.2 Schematics of FACS and MACS. (A) FACS: Cells dispersed in the input 
sample are focused into a single stream at the channel center using sheath flows 
before passing over the detection region. Based on the fluorescence detected the 
cells are then switched into one of the two outlets. (B) MACS: Target cells are 
attached to the ligand coated magnetic beads, thus trapped by the magnetic fields, 
while unwanted cells without magnetic beads attachment flow through the column.  
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Figure 2.3 (A)-(B) Droplet-based FACS. (A) Cells encapsulated in liquid droplets are 
sorted based on their fluorescent intensities. (B) Individual frames indicate the sorting 
of fluorescent droplets. (C) Schematic of optical set-up for microfluidic based FACS. 
Reproduced from  [41], copyright 2006, The Royal Society of Chemistry. (D)-(E) 
Magnetic separation. (D) Principle of free-flow magnetophoresis. The separation 
relies on the variation in the uptake of magnetic particles for different cell populations 
during a given incubation period. Reproduced from [44], copyright 2006, The Royal 
Society of Chemistry. (E) Design of a microfluidic magnetophoretic separator using a 
patterned ferromagnetic wire for blood separation. In a magnetic field, the 
paramagnetic RBCs align along the ferromagnetic wire, while the diamagnetic WBCs 
are forced away. Reproduced from [45], copyright 2006, The Royal Society of 
Chemistry 
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Figure 2.4  Dielectrophoretic cell sorting. (A) Schematic illustrating the principle of 
dielectrophoresis (DEP). In the presence of an inhomogeneous electric field, 
polarizable cells experience strong electrostatic forces directing them either toward 
(positive DEP) or away (negative DEP) from regions of stronger fields. (B)-(C) Photos 
of a microfluidic device with patterned electrodes for separation of live and dead yeast 
cells. The viable cells show a positive response and align along the electrode edges 
(B) while dead cells show a negative response and are pushed away from the edges 
(C). Figure reprinted from [48], copyright 2005, Elsevier. 
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Figure 2.5 (A) Optical separation. Design of a microfluidic optical fractionation system 
for size-based and refractive index based separation. The particle mixture introduced 
through chamber B passes through a 3D optical lattice in the fractionation chamber 
(FC) where strong optical interactions selectively generate separate flow 
paths. Reprinted from  [29], copyright 2003, Macmillan Publishers Ltd. (B) Acoustic 
separation. Schematic illustrating the principle of acoustic separation by standing 
surface acoustic waves generated using interdigital transducers. The varying acoustic 
forces repositions the larger cells closer to the channel center and smaller cells farther 
from the center. Figure reproduced from  [50], copyright 2009, The Royal Society of 
Chemistry. 
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Figure 2.6 (A)-(B) Separation using deterministic lateral displacement. (A) Schematic 
illustrating the separation principle by deterministic lateral displacement (DLD) 
technique. Cells with diameter smaller than the critical diameter stay within the flow 
streamlines, while the larger cells are displaced to the right at each obstacle. (B) 
Schematic of the fractionating device used for separating the blood components using 
DLD. Reprinted from  [37], copyright 2006, National Academy of Sciences, 
USA. (C)-(E) Schematic design of a microfluidic device for size-based isolation of 
cancer cell (CTCs). The isolation regions consist of arrays of crescent-shaped 
isolation wells or cell traps to trap cancer cells while allowing blood cells to sieve 
through.  Figure reproduced from  [53], copyright 2009, Springer Science Business 
Media, LLC. 
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Figure 2.7 (A) Schematic illustrating the principle of pinched flow fractionation. 
Suspended particles are aligned against a microchannel sidewall in the pinched 
segment and are separated according to their sizes as they flow into the broadened 
segment as a result of expansion of the laminar flow sheet. Reprinted from  [68], 
copyright 2004, American Chemical Society.  (B) Principle of hydrodynamic filtration. 
Schematic diagram showing particle concentration and separation into multiple side 
channels. Figure reproduced from  [54] , copyright 2005, The Royal Society of 
Chemistry. (C) Inertial lift force-induced cell separation.  Inertial lift forces exerted on 
cells suspended in a Poiseuille flow. The combined effect of the shear-induced lift 
force and the wall-induced lift force align cells at distinct equilibrium positions based 
on their size. Reproduced from [55], copyright 2009, The Royal Society of Chemistry. 
 
 
Figure 2.8 Affinity-based separation. Schematic of the CTC chip consisting of 
micropost array. Inset showing a scanning electron micrograph of a lung cancer cell 
between two chemically functionalized microposts. Reprinted from  [57] copyright 
2007, Macmillan Publishers Ltd.  
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CHAPTER 3 
IMMUNOAFFINITY MICROFLUIDIC DEVICE FOR RARE CELL 
ENRICHMENT: A MODEL SYSTEM 
 
3.1 Introduction 
Exploring new therapeutic strategies and improving understating of both 
fundamental and disease biology are the driving forces for developing new cell sorting 
techniques, which can be used for separation, isolation or enrichment of a specific cell 
type [1-4]. The challenges in developing these cell sorting techniques involve: (1) 
Biological samples are highly heterogeneous and dynamically living mixtures, where 
cells respond and adapt to physiological changes all the time. The natural variation of 
cells even from the same lineage complicate the studies. (2) Cell samples are complex, 
involving different populations at different abundance levels. (3) The least-
abundance/rare cells are usually of the most importance ones in biological studies, 
diagnostics or clinical applications. As a result, highly efficient techniques to separate and 
sort cells at or close to single cell level are the key direction in rare cell separation.  
Recent developments in lab-on-a-chip devices open new possibilities for the study 
and processing of biological samples in microfluidic devices [5-12]. Microfluidic devices 
provide advantages such as high reaction efficiency due to the high surface area to 
volume ratio, precise operation of fluid flow that helps achieve better control of the 
separation results, reduction of cost, as well as ease of operation without the need for 
sophisticated instrumentation. Microfluidics has begun to play an increasingly important 
role in cell biology [13-15], neurobiology [16-17], tissue engineering [18-20], and 
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clinical diagnosis [21-23]. Many microfluidic devices with different flow channel designs 
have been introduced as cell sorting devices based on selection principles making use of 
both physical and biological affinity properties. Physical-based cell sorting methods are 
designed to separate cells based on their differences in size and deformability [12, 24-26], 
which is not useful and applicable in many rare cell separation because the inherent 
variance of size and deformability of target cells limit the efficiency of separation. 
Biological affinity-based separation techniques are based on the specific biological 
recognition of the target cells. Those techniques used in microfluidics include on-chip 
FACS [9, 27-28], on-chip MACS [24, 29-31], and adhesion-based sorting [8, 32-33]. Bio-
affinity based techniques are highly specific, targeting only cells that express biological 
specific interactions or complementary group of molecules and has the ability to separate 
cells of similar physical characteristics (size and density).  Since on-chip FACS and on-
Chip MACS requires external forces and components, complicated device design and 
fabrication as well as further consideration of post- processing steps to release the labels 
(fluorescent or magnetic) after separation, adhesion based sorting provide the best 
potential among all the other techniques for rare cell separation with good specificity and 
selectivity as well as high throughput. 
The strength of cell-surface adhesion depends on the cell type and the surface used. 
Common surface modification approaches are micro- and nano-structuring of the surface 
and functionalization with specific ligands. These ligands, referred to as cell adhesion 
molecules, are involved in cell-cell and cell-surface interactions and are commonly used 
in the design of sorting, sensing and diagnostic devices to target desired cell types. 
Various nanostructures, including pillars, parallel lines, perpendicular lines, and squares, 
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have been demonstrated to show different adhesive strength to different types of 
cells [34]. However, the story behind the variation in cell adhesion to different 
topography is not well understood and thus hard to design rationally and probably not 
applicable to all biological systems. In contrast, ligand-specific cell adhesion is a more 
reliable approach which has wide applications. Specificity of cell adhesion in 
microfluidic devices can be achieved using proteins, peptides [35-36] and aptamers [37-
39] to capture desired cell types. Using peptides or aptamers to recognize cells are 
emerging fields. Their small size and inexpensive production make them better 
candidates in cell targeting compared to proteins. However, selecting the right peptides 
and aptamers is still challenging and can be time consuming, which limits their 
applications into very few practical areas right now. Proteins, especially antibodies that 
are generated against specific proteins on the target cell in a natural process, are more 
conventional and the most widely used ligands for cell recognition [8, 40].   The use of 
antibodies as ligands is known as immunoaffinity based isolation. In our project, we use 
the antibody against CD34, which is a transmembrane protein expressed on hematopoetic 
stem and progenitor cells (HSCs), but not on any mature blood cells, to recognize HSCs. 
Other than topography and cell adhesive protein, shear stress and flow rate are 
important factors affecting cell adhesion in microfluidic devices as well [8]. The main 
distinction of cell adhesion in microfluidic devices compared to conventional cell 
adhesion flasks is the precise characterization of flow pattern and the shear stress 
generated. In general, adhesion rate decreases with increasing flow rate as well as shear 
stress, which is an important consideration when designing microfluidic devices for cell 
sorting at different locations in the microchannels.  
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Here we report an immunoaffinity-based microfluidic device designed to selectively 
capture HSCs from a mixture of cells (e. g., cells in blood). This HSC enrichment 
platform is designed such that high purity (> 90%) and high throughput (104 cells/s) can 
be achieved. Surface adhesion and shear stress will be studied and characterized in a 
model system with a mixture of cell lines designed to mimic the relative populations of 
HSC and other cell types found in blood. 
3.2 Materials and Methods 
3.2.1 Surface modification and characterization 
Glass slides covered with 400-Å-thick gold films were prepared by electron-beam 
evaporation of Au at a base pressure of 10-6 Torr onto cleaned glass slides which were 
precoated with a 20-Å chromium adhesion promoter. 
The protein-coated substrates were prepared with self-assembled monolayers (SAMs) 
of carboxylic acid-terminated alkanethiols, self-assembled on gold film. The gold films 
were immersed overnight in an ethanolic solution containing 16-mercaptohexadecanoic 
acid (MHD) and 11-mercaptoundecan-1-ol (MUD) at a 3:1 molar ratio. The coated cover 
slips were then rinsed with ethanol and dried under a nitrogen stream. 
The freshly SAM modified gold substrates were brought in contact with the PDMS 
mold of the multichannel pattern (five channels at 500 m x 1 cm x 50 µm in parallel)  
and then pressed between two pieces of Plexigla, with defined inlets and outlets, by 
binder clips as shown in Figure 3.1. The microchannels were then flushed first with 
ethanol to eliminate bubbles inside the device and then with phosphate buffered saline 
(PBS, 10 mM phosphate, 0.14 M NaCl, pH 7.4).  
To covalently immobilize proteins on the SAMs, the terminal carboxylic acid groups 
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on the SAMs were activated with EDC/NHS linkers, 3.8 mg EDC/mL, 6.7 mg NHS/mL 
in PBS, for 15 min at room temperature. Thus, the activation reagents were introduced 
only to the regions defined by the microfluidic channel. 
Subsequently, the activated SAMs were rinsed with PBS to remove the unreacted 
EDC/NHS reagents. Mouse anti-human CD34 antibody (CD34Ab) solution, at 
concentrations between 20-100 g/ml in PBS, was then pumped through the 
microchannel at a flow rate of 0.1 ml/hr at room temperature using a syringe pump to 
allow the antibodies to bind to the surface.  After antibody immobilization, the 
sandwiched device was disassembled and the surface of the substrate was rinsed with 
PBS.  The remaining reactive sites on the SAMs were then blocked by treating the cover 
slips for 15 min with 10% BSA in PBS.  Finally, the substrates were rinsed consecutively 
with PBS and sterile water and dried in air. 
The binding kinetics of CD34Ab to the surface and the surface density of CD34Ab 
were studied using an in-house-built surface plasmon resonance (SPR) setup.  The SPR 
flow cell containing the SAM-modified gold substrate was rinsed with water and then 
PBS for 15 min. The monolayers were then activated with the EDC/NHS coupling agents 
for 15 min at a flow rate of 0.7 ml/min, followed by rinsing with PBS for 5 min.  
CD34Ab was then introduced at a flow rate of 0.1 mL/min. The SPR cell was finally 
rinsed with PBS and then water for 10 min at a flow rate of 4 mL/min.  
To visualize the protein, the protein coated surface was stained with a specific 
antibody, Alexa Fluor® 488 goat anti-mouse IgG (H+L) (1:50 in 10% BSA/PBS) for 10 
min at room temperature. The substrate was then rinsed with PBS, treated with an 
antifade kit to maintain the fluorescence intensity and then covered with a microscope 
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cover slip. Finally, the fluorescent multichannel was visualized under a fluorescence 
microscope equipped with a camera. Digital images were captured and analyzed using 
Image-Pro Plus software, version 6.1. 
To further characterize the functionality of CD34Ab in recognizing CD34 antigen, 
CD34 positive KG1a cells (primitive human acute myeloid leukemia cell line) were 
incubated with the CD34Ab coated surface for 5 min. at room temperature. The unbound 
cells were gently washed away with PBS by repeated pipetting.  
3.2.2 Optimization of surface affinity to CD34 positive cells 
CD34Ab is available both in polyclonal and the monoclonal form. Polyclonal 
antibodies are antibodies that are obtained from different B cell resources. They are a 
combination of immunoglobulin molecules secreted against a specific antigen, each 
identifying a different epitopes. Monoclonal antibodies are mono-specific antibodies that 
are made by identical B cells all identifying the same epitope. Within each class different 
clones of CD34Ab exist as well.  Not all antibodies have the same strength of binding.  
Some bind strongly and some weakly, depending on the chemical structures of the 
antibodies as well as particular epitopes of the antigen they are targeting.  In addition, the 
covalent immobilization approach used to attach CD34Ab targeted the primary amines on 
the CD34Ab.  Depending on the position and availability of the primary amines on each 
antibody, the orientation and activity of the immobilized antibody would make the 
resulting adhesive strength of the surface very different.  Rabbit anti-human Polyclonal 
CD34Ab, My10 (Class I monoclonal), Qbend10 (Class II monoclonal), 4H11 (Class III 
monoclonal), 581 (Class III monoclonal), ICH-3 (Class III monoclonal) were tested in the 
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enrichment experiment for their specificity, selectivity, and strength of binding towards 
CD34 positive cells under the same experimental protocol.  
3.2.3 Quantitative study of shear stresses   
The adhesion between introduced cells and the CD34Ab coated surface was studied 
by using an in-house-built parallel plate flow chamber (Figure 3.2), which provides a 
constant shear stress throughout the chamber at a constant flow rate. Shear stress at the 
wall ( t ) exerted on the suspended particles depends on the geometry of the channel (h: 
depth, l: length, w: width), the volumetric flow rate (Q), and the viscosity of suspension 
(µ), which is given by the following equation: 
6 Qt
hlw
  
 Cells were exposed to a wide range of shear stresses, which was achieved by 
introducing the cell suspension under different flow rates. The relationship between the 
shear stresses and the volumetric flow rate in the constant shear stress chamber was 
calibrated and determined as:  
0.3741 0.2826t Q   
The running buffer (PBS or cell media) was placed in a water bath at 37 C before 
each experiment.  The cell suspension was loaded into a 1 mL syringe and was pulled 
from the outlet into the flow chamber at the rate of 0.05 - 0.1 mL/min using syringe 
pump.  After introduction of the cell solution, the CD34Ab coated surface in the chamber 
was incubated with the cells for 10 - 20 minutes.  Digital images and videos were taken 
and analyzed using Image-Pro Plus software, version 6.1. A series of flow rates at 0.5 
mL/min, 1 ml/min, 2 mL/min, 5 mL/min, 10 mL/min, 15 mL/min, 25 mL/min, 40 
mL/min and 60 mL/min were applied to the system to wash away the unbound and non-
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specifically bound negative cells, and to detach the captured positive cells.  Each flow 
condition was initiated for 30 seconds, stopped, and then an image of each channel (same 
spot) was captured.  Shear stress corresponding to each flow rate was calculated from the 
calibration curve (Figure 3.2B). An automated stage was used to help capture the same 
locations within each channel from experiment to experiment. The number of positive 
cells and negative cells were counted and compared in each image.  Images were 
analyzed using ImageJ software.  
3.2.4 A model system for HSC enrichment from blood 
To characterize the interaction and specificity of the CD34Ab coated surface towards 
CD34 antigen on the cells, a series of sample conditions were established as model 
systems resembling the HSC enrichment condition before the HSC enrichment from 
blood was studied.  
Two phenotypically pure cell lines, CD34 positive / CD133 negative KG1a cells, and 
CD133 positive / CD34 negative Weri-Rb-1 cells (human retinoblastoma cells), were 
mixed at a 1 to 9 ratio with a final concentration of 1 × 107 cells/ml. The enrichment of 
two types of cells on CD34Ab (40 µg/ml) or CD133Ab (40 µg/ml) coated channels 
respectively were studied at varied shear stresses as mentioned in Section 3.2.3.  
To increase the complexity of the CD34 negative cell populations as well as to 
evaluate the potential for high throughput processing, fresh human or pig white blood 
cells (less than 0.001% CD34 positive cells) were spiked with 1% KG1a at a final 
concentration of 1 × 108 cells/ml. 
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Finally, frozen human bone marrow mobilized peripheral blood (containing 0.1-5% 
CD34 positive blood cells) was spiked with 1% KG1a at a final concentration of 1 × 108 
cells/ml. 
KG1a cells were stained with CFSE (green fluorescent dye, carboxyfluorescein 
diacetate, succinimidyl ester) to be distinguished from CD34 negative cells. 
3.2.5 Blood handling protocol 
Fresh human and pig white blood cells were used in model system as a source of 
CD34 negative cell.  Human/pig white blood cells were obtained from fresh human/pig 
blood by removing red blood cells using Histopaque-1077 and resuspended in 10% fetal 
bovine serum (FBS) supplemented RPMI-1640 at desired experimental concentration.  
Cryopreserved bone marrow mobilized peripheral blood (from Northwestern hospital) 
was used for HSC enrichment. Cryopreservation of bone marrow or HSCs was performed 
in Northwestern hospital to store the cells after collection for future use.  HSC or bone 
marrow samples had to be thawed to assess the post-thaw nucleated cell recovery and cell 
viability of the sample prior to further manipulation or use. The cell aliquot (product bag) 
was first placed in a zip-lock bag and thawed in 37 °C water bath with gentle agitation.  
The cell suspension was gently transferred to a few 50 ml centrifuge tubes at 20 ml per 
each tube when only a few ice chips remained. 20 ml of ice cold 5% human serum 
albumin (HSA) and 10% citrate dextrose solution (ACD) supplemented RPMI-1640 was 
added drop by drop to the 50 ml tube using a 20 ml syringe, followed by gentle mixing.  
The cell suspension was then centrifuged for 3-5 minutes at ~ 900 RPM (400 x g) at 
room temperature.  The cell pellet was gently resuspended in 5 ml of fresh medium drop 
by drop. Another 35 ml of fresh medium (as mentioned above) was added to the 
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suspension slowly. The cell suspension was incubated for 1-2 hours at room temperature.  
Cell count and viability was performed and calculated right before the enrichment 
experiment.  
3.3 Results and Discussion 
3.3.1 Surface functionalization  
The surface density of the bound CD34Ab was determined by fitting the Fresnel 
reflectivity equations to the change in the plasmon resonance angle following protein 
adsorption. For these analyses, we used a refractive index of 1.46 for the bound CD34Ab.  
The surface density of Qbend10 (20 µg/ml) was 19800 pg/dm2. The surface saturation of 
Qbend10 was reached after four hours of continuous flow injection at a concentration of 
20 µg/ml at room temperature.  
Fluorescence was observed in the microchannels after immunostaining (Figure 3.3A), 
indicating that Qbend10 was successful immobilized and that the protein was still active.  
A high density of Kg1a cells was captured on the Qbend10 coated surface after being 
incubated for 5 minutes, which indicated that the reactivity of the Qbend10 was well 
retained after immobilization (Figure. 3.3B).  
3.3.2 Optimization of surface adhesion towards CD34 positive cells 
Among all the polyclonal and monoclonal antibodies studied, Qbend10 showed best 
adhesive strength and specificity. My10 provided specificity but much less adhesive 
strength comparing to Qbend10, which significantly limited the capture efficiency of any 
My10 coated surface. Other monoclonal CD34Abs show little or no interactions with 
CD34 positive cells after immobilization. These results indicated degradation of the 
protein after immobilization.  Polyclonal CD34Ab offered weak adhesive strength to not 
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only the CD34 positive cells but also CD133 positive cells and some subpopulations in 
fresh human white blood cells, thus providing little specificity or selectivity to CD34 
positive cells.  
3.3.3 Optimization of flow rate and shear stresses  
Since the cells are captured in a dynamic flow, flow rate and shear stress profile are 
the two key factors in determining the overall performance. The flow rate determines the 
duration of contact between cells and surface, while the shear stress quantifies the 
adhesion required for capturing and releasing cells. The optimum shear stresses for 
capturing and releasing cells in different model systems were studied in a constant shear 
stress chamber.  
As a model system, we used mixed batches of Kg1a and Weri-Rb-1 cells, which were 
isolated using CD34Ab and CD133Ab coated surfaces respectively. The experiments 
using these cell mixtures in the shear stress chamber allowed the study and identification 
of shear stress ranges that either capture positive cells, detach the captured negative cells, 
or that potentially release the captured positive cells for each type of surface (Figure 3.4).  
Significant numbers of cells were captured in both channels at a shear stress of 0.29 
dynes/cm2 and a flow rate of 0.05 ml/min. In this case, 18% of the cells in CD34Ab 
coated channels are CD34 positive Kg1a cells (the number of target cells on the surface 
divided by the total number of cells on the surface), while 95% of the cells in CD133Ab 
coated channels are CD133 positive Weri-Rb-1 cells. These results indicated that both 
modified surfaces provided robust adhesion and good specificity to the target cells.  The 
purity of captured cells in the CD133Ab microchannel was expected to be much higher 
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than the purity in the CD34Ab microchannels, since the number of Weri-Rb-1 cells was 
nine times higher than that of Kg1a cells in the original samples.  
The number of captured cells in both microchannels decreased with increasing shear 
stresses, a phenomenon that was more profound in the CD34Ab coated microchannel.  
By increasing the shear stress from 0.36 to 7.5 dynes/cm2, the number of nonspecific 
bound negative cells on CD34Ab coated surface decreased significantly, with only 
19±4% of cells left. However, 95±3 % of target cells still remained on the CD34Ab 
surface during the same shear stress increase. As a result, the purity of the captured 
increased from 18±2 % to 55±3 % in CD34Ab coated microchannel. (The purity 
increased from 95±1 % to 96±0.8 % in CD133Ab coated microchannel.) These results 
suggest that the purity of enrichment could be significantly enhanced by slightly 
increasing the flow rate, and thus the shear stress.  
Furthering increasing the shear stress continuously released negative cells, and CD34 
positive cells started to be detached from surface significantly at the shear stress of 15 
dynes/cm2. However, even at a shear stress of 38 dynes/cm2, 75±5 % of Kg1a and 
95±2 % of Weri-Rb-1 still remained on the CD34Ab coated and CD133Ab coated 
surfaces respectively. These numbers suggest that the activities of the two antibodies was 
retained after immobilization and the interactions between the antibody-coated surface 
and the antigen-presenting cells were very strong and specific, thus providing a wide 
window of flow rate and shear stress to operate for purity optimization, which made it 
promising for exploring the system to enrich rare population such as HSC enrichment 
from blood.  However, the nonspecific binding at low flow rate and low shear stress on 
CD34Ab coated surface was high, which limited the capture efficiency since a large 
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fraction of the active area was occupied by negative cells. Even though the negative cells 
were detached eventually with increasing shear stresses, their presence precluded the 
chance for the target cells to interact with the surface.   
To decrease the nonspecific binding and optimize the flow conditions for higher 
throughput, two different flow rates (0.05 ml/min, 0.30 dynes/cm2 and 0.1 ml/min, 0.32 
dynes/cm2) were used to introduce cell suspension into the constant shear stress chamber 
at two different sample concentrations (1% CD34 positive Kg1a cells in a final 
concentrations of 5× 107 cells/ml and 4 × 108 cells/ml respectively). The purity of cells 
captured initially after introducing the cell suspension was 84±2 % at 0.1 ml/min and 
0.32 dynes/cm2, compared to 21±4 % at 0.05 ml/min and 0.30 dynes/cm2 at both 
concentrations.  The number of Kg1a cells captured under low flow rate was roughly 
twice that under high flow rate.  This result indicated that the flow rate of 0.1 ml/min was 
high enough to significantly limit nonspecific binding, but still low enough to allow 
capture of most of the target Kg1a cells. In effect this is a compromise to the capture 
efficiency, defined asthe number of target cells captured on the surface divided by the 
number of target cells being passed through the device. Consequently, flow rates within 
the range of 0.05-0.1 ml/min should provide an optimum enrichment performance 
depending on the original sample conditions and the tendency of nonspecific binding.  
The number of KG1a captured under high concentration of total number of cells is 
7.5 times of that under low concentration (Figure 3.5), which was roughly the same ratio 
between the two initial sample concentrations. This result indicated that the capture 
efficiency of enrichment was not related to the original concentration of the sample when 
the surface was not saturated, and that saturation was reached at roughly 4 × 106 KG1a 
52 
 
cells per sample.  The results in this figure were encouraging, since is the number of cells 
captured was already more than the number of HSCs we would like to capture later on 
(typically 0.5-2 × 106 HSC cells in every 108 blood cells).   
3.3.4 CD34 positive Kg1a cell enrichment from human and pig fresh blood 
One of the challenges for HSC enrichment from blood is that the various types of 
white blood cells in the samples express all different types of receptors on their surface, 
which might have weak or even strong interactions with Qbend10.  In order to take into 
consideration the nonspecific binding associated with real blood samples, Kg1a spiked 
fresh pig white blood cells and fresh human white blood cells were used as advanced 
model systems to evaluate the specificity and selectivity of the Qbend10 coated surface 
for Kg1a enrichment.  Human white blood cells isolated from fresh peripheral blood were 
chosen as a human CD34 negative population since only a negligible number of CD34 
positive HSCs (less than 1 out of 104 white blood cells) is present in peripheral blood.  
Pig white blood cells were chosen as a human CD34 negative population because pig 
CD34 has no cross reactivity with human CD34Ab.  
The obtained purities of enrichment were 95±0.9% for pig white blood cell sample 
and 92±3% for human white blood cell sample, which were even higher than the purity of 
enrichment from Weri-Rb-1 cells.  These results indicated that the interactions between 
Qbend10 coated surface and all the human and pig white blood cell populations were 
minimal, which suggested that interference or intrinsic nonspecific binding will probably 
not be an issue for HSC enrichment from blood using our Qbend10 immobilized device.  
However, the capture efficiency (13±3%) in the enrichment from human blood were 
lower than that from pig blood (18±5%) or Weri-Rb-1 (21±3%), which suggested that the 
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remaining trace amount of plasma or red blood cells might have reduced the activity of 
the Qbend10 coated surface.  
3.3.5 HSC enrichment from bone marrow mobilized peripheral blood  
Finally HSCs were enriched from freshly thawed human bone marrow mobilized 
peripheral blood (1% CD34 positive population). Three Qbend10 coated microchannels 
(Qbend10 was immobilized at three solution concentrations of 20, 40, 60 µg/ml 
respectively) and one isotype-control coated microchannels (mouse anti-human IgG1 was 
immobilized at the solution concentration of 100 µg/ml) were investigated for HSC 
enrichment in the aforementioned constant shear stress chamber.  One ml of blood 
containing 1 × 108 cells was introduced into each chamber.  Significant amounts of cells 
were captured inside the three Qbend10 microchannels compared to isotype control 
channels (Figure. 3.6A & 3.6C). Cells captured in all three CD34Ab channels only 
gradually detached with increased shear stresses, and the numbers of cells that remained 
on the Qbend10 coated surfaces were correlated with the initial immobilization 
concentrations of Qbend10 (Figure. 3.6B). Furthermore, after being exposed to a shear 
stress of 38 dynes/cm2, when a purity of 94% was suggested from previous Kg1a 
experiment, about 2× 103 cells still remained in the microchannel with the highest 
Qbend10 immobilization concentration. This result suggested that HSCs also showed 
strong interactions with the Qbend10 coated surface. The capture efficiency of 
enrichment was 7±2 % with a throughput of 106 cells/s. This means that a 5 cm × 10 cm 
antibody coated surface should be sufficient for capturing 1 × 106 HSCs from a mixture 
that contains a 1% HSC concentration.  
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3.4 Conclusions 
An immunoaffinity-based microfluidic technique for rare cell enrichment was 
evaluated and validated using a model system and it was applied in an actual HSC 
enrichment experiment. Covalent immobilization of CD34Ab provided a robust, stable 
and reproducible surface for enrichment. Qbend10 mouse anti-human CD34 antibody, 
chosen from a few other types and classes of CD34Ab, provided strong binding, good 
specificity and selectivity for the enrichment of CD34 presenting cells.  Shear stresses to 
characterize immobilized Qbend10 on the surface and Kg1a as well as HSCs were 
quantified. The effects of different flow rate and shear stress for introducing cell 
suspension to the device, for detaching nonspecific bound cells, and for releasing target 
cells after enrichment were studied. The results indicated that a Qbend10 coated flat 
surface design was efficient and promising for HSC enrichment from blood. Furthermore, 
scaling out to a larger capture surface area, for example by introducing three dimensional 
features, should allow for the efficient capture of HSCs from blood at high purity, and at 
a throughput sufficient for clinical application. Such a highs surface area cell enrichment 
platform will be discussed in Chapter 4.  
3.5 Figures  
 
Figure 3.1 (A) Photo and (B) schematic of a microfluidic device for CD34Ab 
immobilization.  
 
 
A B
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Figure 3.2 (A) Perspective view and (B) schematic side view of the constant shear 
stress chamber 
    
 
 
 
 
Figure 3.3 Characterization of Qbend10 immobilization. 20µg/ml Qbend10 was 
immobilized in a 500 µm wide × 1 cm long channel. (A) Surface stained with the 
conjugated secondary antibody Alexa488. (B) Surface after incubation with KG1a cells 
for 5 min. and rinsing the surface to remove unbound cells. Scale bar is 100 µm. 
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Figure 3.4. CD34+ and CD133+ cell enrichment from a mixture of Kg1a and Weri-Rb-1 
cells at a ratio of 1 to 9 using the constant shear stress chamber. (A) Total number of 
cells captured on CD34Ab and CD133Ab coated surfaces in imaged view, which can be 
converted to the number of cells in the whole channel with a scaling factor of 25.  (B) 
Percentage of Kg1a cells present in the CD34Ab channel and Weri-Rb-1 cells in the 
CD133Ab channel.   
 
 
 
 
 
Figure 3.5 Number of Kg1a captured as a function of four different sets of conditions.  
The experiments were performed using a mixture of 1% Kg1a cells at two different total 
cell concentrations and at two different flow conditions. The three colored lines indicate 
results from three separate experiments in identical microchannels. 
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Figure 3.6. HSC enrichment from human peripheral blood using shear stress chamber. 
A & C: Number of cells in pictured viewed which can be converted to the number of cells 
in whole channel with a scaling factor of 20. A was analyzed from one spot per channel, 
while C was from three spots per channel. B: Normalized percentage of cells captured 
on surface from A. The numbers in the legends after the antibody indicated the 
concentration of antibody (in µg/ml) used for immobilization.  
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CHAPTER 4 
SILICON MICROPOST BASED IMMUNOAFFINITY CHIP FOR CELL 
ENRICHMENT: DESIGN PRINCIPLES 
 
4.1 Introduction 
This chapter will describe the design of an affinity-based microfluidic device for 
the capture and enrichment of specific types of cells for both clinical applications and 
fundamental research. This approach provides great specificity and selectivity, label 
free separation without a preprocessing step, and easy, fast, cost-effective, and highly 
implementable detection systems, which makes it ideal for enrichment or rare 
cells [1-4]. This effort has the potential to yield a portable, easy to use and 
inexpensive point-of-care device that can be applied, for example, in early stage 
diagnosis, blood transfusion and in regenerative medicine for separation of stem cells 
and progenitor cells [5-7], cancer cells  [1, 8-9] and other rare cell types [10].  
Identifying suitable adhesive ligands and coming up with appropriate designs are the 
two key challenges that need to be addressed to obtain affinity-based cell sorting 
devices capable of achieving high purity, high capture efficiency and high throughput. 
For HSC enrichment, Qbend10 (Class II CD34 antibody) was proved to provide high 
selectivity and specificity to CD34 presenting cells, as discussed in Chapter 3. The 
way we addressed the second unsolved problem of obtaining an appropriate device 
design for high capture efficiency is discussed in this chapter.  
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Capture efficiency in adhesion based microchips relies mainly on the amount of 
surface area available for binding and the frequency of the interactions between the 
cells and the surface. Microposts and surface ridges or herringbone structures have 
been introduced in affinity based microchips for improved capture efficiency in rare 
cell enrichment, particularly for the capture of circulating tumor cell isolation [4, 
11-12]. In laminar, uniaxial flow conditions, cells follow streamlines and exhibit 
minimal diffusion across the channel [13].  The relative simple and controllable flow 
profile is beneficial for characterizing the velocity and shear stress in the system, 
which are critical in determining the enrichment performance in affinity based 
devices. However, the lack of mixing limits the potential to largely increase the 
number of collisions between the cell and the surface of the device, which is critical 
for capture of the target cells.  Surface ridges and herringbones can disrupt the 
streamlines and induce eddies, spiral flows, or even chaotic advection, thereby 
increasing the potential for interaction between the cells and the capture surface. 
However, the chaotic flow patterns induced by these structures greatly complicate the 
flow behavior in the channel, rendering prediction of the velocity and shear stress 
profiles, and from that the performance of a given device in cell enrichment, more 
difficult. Herringbone structures are most valuable in isolating very rare populations 
of cells where the capture efficiency is the priority and purity can be compromised, 
such as circulating tumor cells from blood, in which only1 out of 109 cells is a target 
CTC. In contrast, micropost structures produce a much more predictable laminar flow 
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pattern. As will be described in this chapter, the micropost structures offer more 
options to fine-tune the balance between capture efficiency and purity.  
In HCS enrichment for clinical transplantation, high purity is required to 
minimize risks of life-threatening diseases and complications due to the 
contamination white blood cells [14-16]. High capture efficiency is also important 
since the sample needs to be processed within a short time frame and high efficiency 
guarantees that less time is required to process a smaller volume of sample to obtain 
the target number of the cells for transplantation [17-18]. Consequently, micropost 
features were introduced in the HSC enrichment microchip to balance the 
requirements of purity and capture efficiency simultaneously. In this chapter a range 
of different micropost designs are modeled and experimentally validated using a 
variety of model systems. The application of the best chips designed in this Chapter 4 
will be applied for HSC enrichment in Chapter 5.    
4.2 Materials and Methods 
4.2.1 Micropost fabrication  
Conventional high-resolution photolithography and deep reactive ion-etching 
were used to fabricate silicon micropost arrays. Silicon wafers (University Wafer, 
South Boston, MA) was spin coated with photoresist (AZ 4620, Clariant, Charlotte, 
NC). A mask aligner (Electronic Vision 420, EV Group, Tempe, AZ) was used for 
patterning photoresist using photolithography. The pattern was then developed and 
subsequently etched to 70 µm via deep reactive ion etching (STS Pegasus ICP-DRIE, 
SPTS Technologies, San Jose, CA). A pattern composed of 50,000 microposts in the 
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area of 1 cm x 1.5 cm was obtained. The dimensions of the silicon microposts were 
measured by surface profilometry (Alpha-Step IQ Surface Profiler, KLA-Tenco, CA) 
and scanning electron microscopy (SEM; JEOL6060LV, JEOL USA, Peabody, MA).  
4.2.2 Surface functionalization 
The surface of the immunoaffinity microchip was functionalized with CD34 
antibodies using avidin–biotin chemistry. The silicon surface on the microchip was 
firstly activated with Piranha solution (H2SO4:H2O2=3:1) for 15 min. at 120 ºC, then 
silanized with 4% (v/v) 3-mercaptopropyl trimethoxysilane (Sigma Aldrich, St Louis, 
MO) in ethanol at room temperature for 45 min. 1 mM N-γ-maleimidobutyryloxy 
succinimide ester (Thermo Fisher Scientific, Rockford, IL) in ethanol was then allowed 
to react with the surface for 20 mins. Neutravidin (Thermo Fisher Scientific) of 10 
mg/ml, and 0.1% Tween20 in phosphate buffered solution (PBS) was then introduced 
on the surface at room temperature for 30 min. Finally biotinylated CD34 antibody 
(Qbend10-biotin, Lifespan Biosciences, Seattle, WA) at a concentration of 80 mg/ml 
in PBS with 1mg/ml of mPEG-biotin (MW 1000, Nanocs, New York, NY) and 0.1% 
Tween20 was allowed to react for 30 min. The functionalized surface was air dried and 
stored at room temperature for up to two weeks until use. 
4.2.3 Supporting device for cell enrichment  
A Polyether ether ketone (PEEK) based supporting device was fabricated to 
couple the microchip with a microfluidic pumping system to provide flow through the 
chip (Figure 4.1). The silicon chips were placed in 4 cm × 3.9 cm PEEK manifold 
consisting of a top piece and a base. The top piece provides a glass window in the 
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center for visualization, a thin groove outside the glass window to place the silicon 
o-ring for reversible leak-proof pressure sealing, and inlet and outlet ports on the side 
to direct the fluid. The base provides a groove to secure the silicon chip in place.  
The top and base were joined by six metal screws on the side. For ease of operation 
the port dimensions are such that standard lure fittings can be used. Two three way 
valves were connected to the inlet and outlet ports to provide flexibility in fluid 
manipulation during the experiments. A microfluidic syringe pump was connected to 
the outlet through tubing to introduce negative pressure to the system to direct the 
flow. A 1 ml solution comprised of 5% BSA in PBS was introduced to the assembled 
device before each experiment to prevent non-specific binding of untargeted cells.  
Then 0.5 ml of cell mixture was introduced into the device at a flow rate in the range 
of 10-25 µl/min for 30-45 mins to allow the target cells to be captured. After that, a 
higher flow rate of 100-500 µl/min was used to wash away any non-specifically 
bound cells.   
4.2.4 Cell capture model using COMOSL Multiphysics  
In order to understand and predict the flow behavior as well as the interactions 
between the cells and the micropost, two dimensional (2D) and three dimensional (3D) 
models were built using the commercial finite-element-method (FEM) software 
COMSOL Multiphysics (COMSOL, Stockholm, Sweden). In the 2D model, 
microposts of 30 µm diameter and 30, 40, 50, 60 µm spacing, respectively, in an array 
with an area of 1 mm x 2 mm was used as a representative structure for the much 
larger micropost array used in the actual experiment. The Navier-Stokes equation for 
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incompressible flow was used to define and describe the flow behavior in the 
micropost array. Flow velocity and shear stress, the two significant parameters in the 
cell separation experiments, were solved in all different arrangements of the 
micropost arrays (Figure 4.2A&B). To predict the cell capture events in the micropost 
array, a PDE (partial differential equation) model was set up to solve the distance 
between the cells in the streamline to the surface of the post (Figure 4.2C).  The 
following assumption was made to simplify the model: (1) The cells were considered 
as round particles in 2D and sphere in 3D, with no elasticity for deformation; (2) The 
diffusion of the cells in the stream was negligible; and (3) The velocity of the cells in 
z direction was always assumed to be zero, because the gravity forces are balanced by 
the buoyancy forces. A particle tracing model was further applied to the final solutions 
of the Navier-Stokes and PDE model to visualize the capture efficiency in a given 
micropost design (Figure 4.2D). In the particle tracing model, cells were set to stop 
and be captured on the micropost when all the of the following conditions are met: (1) 
the distance between the cell and the surface or the post is equal to or less than the 
radius of the cell; (2) the shear stress the cell was experiencing was less than a critical 
value; (3) the velocity of the cell was less than a critical value; and (4) the chance for 
the capture event to happen when all the above three conditions are met is 100%.  
Since cell capture is a dynamic process where the captured cells on the posts also 
distort the streamline that subsequent cells travel in, a Matlab code was written to 
extract the coordinates of the cells captured on the post for the first round and 
accordingly circles representing the captured cells were added in the device geometry, 
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which helped to predict cell capture events after cells started to build up on the device. 
The capture efficiency was calculated by the number of cells captured in the post 
region divided by the number of cells that flowed through the device without being 
captured.  
4.2.4.1 The Navier-Stokes Equation 
The model firstly computes the fluid’s velocity components u = (u, v) in the x and 
y directions. The stationary incompressible Navier-Stokes equations are used to build 
the model.  
 
The first equation is the balance of momentum from Newton’s second law. The 
second is the equation of continuity, where zero on the right-hand side states that the 
fluid was incompressible. The following variables and parameters appeared in the 
equations: η is the dynamic viscosity, ρ was the density, u is the velocity field, p was 
the pressure, and F is a volume force field. The velocity solution is obtained by 
applying the following boundary conditions:  
u = 1×10-4 m/s; inlets,  
p = 0; outlets,  
u = 0; walls 
The inlet condition is set to match the velocity used in the actual experiments for 
introducing cells to allow the interactions between the cell and the device surface. The 
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zero-pressure condition is applied to the outlet.  The no-slip condition is applied to 
all the walls of the channel and around the microposts.  
4.2.4.2 General form partial differential equation  
A general form PDE was added to the original model with a single variable 'phi', 
which represents the distance in meters from the posts. The PDE solved the distance 
equation for phi:  
abs (grad (phi)) = 1 by solving equations:  
𝛻⋅𝛤=𝐹 
where 𝛤 is the flux vector (-phix *10-6, -phiy*10-6), and 𝐹 is the source term 𝐹= 
1-((phix)2+(phiy)2) 
The boundary conditions used are Dirichlet boundary conditions on the post surfaces: 
−n⋅𝛤=0; phi=0  
and Neumann boundary conditions on the other boundaries: 
 −n⋅𝛤=0  
4.2.4.3 Particle tracing model 
The trajectories of cells (path lines) in a flow field, are visualized in the static 
particle tracing model. Cells are assumed to be massless particles in the model to save 
memory in solving process. This assumption is proved to not compromise the 
accuracy of the solutions after its results are compared with those of “with mass” 
model. The path lines are generated by solving the fundamental equation of motion 
for path line x. 
 
70 
 
The capture event is defined in the velocity equation: 
u = u × ((phi > capture_distance) || (u > critical_velocity) || (sr > critical_shear 
rate)) 
v = v × ((phi > capture_distance) || (v > critical_velocity) || (sr > critical_shear 
rate)) 
where u and v are the velocity in x and y direction respectively, sr is the shear rate.  
The particle tracing velocity fields are set to zero when the cell is closer to the surface 
of the device than the given capture distance (radius of the target cell), and the 
velocity of the cell is smaller than the given critical velocity to allow sufficient time 
for the bonding events to happen, and the shear rate of the cell is smaller than the 
given critical shear rate so that the bonding force between the cell and the surface can 
overcome the shear force to retain the cell on the surface. 
4.2.4.4 Dynamic capture efficiency 
Since all the models discussed above are static models, the current simulation 
doesn’t take into consideration how the captured cells influence the streamline and 
path line in the device, which is also very critical in such microfluidic device where 
the streamline is very sensitive to changes in the device geometry. To take into 
consideration of the influence of captured cells on the device acting on the flow 
pattern and the capture of the future cells, a Matlab code is written to extract the 
coordinate information of the captured cells in the previous round of capture and to 
draw circles representing these cells according to the extracted coordinate information 
as additional geometry in the device in the following round of capture.  Since the 
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cells on the surface are only serving as obstacles to deviate the streamline but not able 
to capture cells, the boundary conditions of these cell-representing circles are set to be 
no slip walls in the Navier-Stokes model and Neumann in the PDE model.  Four 
successive rounds of capture are modeled in all different device designs before the 
captured cells start to clog the device. 
4.3 Results and Discussion 
4.3.1 Experimental protocol optimization: surface functionalization 
The introduction of microposts on the silicon chip largely increases the surface 
area as well as the chance of interactions between the cells and the surface.  
However, the presence of the numerous microposts could alter the surface properties 
of the silicon wafer. The increased surface area due to microposts requires additional 
surface energy to allow the surface to be evenly wetted by the reagents in surface 
functionalization, which render the surface more hydrophobic. The surface 
functionalization process started with an ultra-hydrophilic surface with hydroxyl 
groups on the silicon wafer. As the bi-functional linker was introduced, the surface 
became more and more hydrophobic. However, the neutravidin in PBS is very 
hydrophilic, which resulted in challenges in surface functionalization. In order to 
bridge the difference in hydrophobicity between the surface and the reagents to 
achieve more homogenous and reproducible antibody immobilization, a small 
surfactant molecule Tween20 was added into the neutravdin aqueous solution as well 
as the biotinylated-CD34 aqueous solution. The addition of Tween20 was proven to 
significantly increase the successful rate of antibody immobilization.  
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On the other hand, the increased surface area as a result of micropost fabrication 
also introduced small defects thus increased roughness on the surface of the device 
due to DRIE process. Again, the increased surface roughness led to more hydrophobic 
surface, which was more prone to non-specific binding. In order to minimize the 
roughness induced non-specific binding, biotinylated polyethylene glycol (PEG) was 
added into the final CD34Ab immobilization steps to render the final surface more 
hydrophilic.         
4.3.2 Critical parameters for cell capture in immunoaffinity device  
To allow the cells to be captured on the device, strong bonding between the 
antibody on the device surface and the CD34 on the cell surface are required to 
overcome the shear stress cells are experiencing.  As a result, whether the target cells 
can be captured on the surface is determined by three conditions: (1) the distance 
between the cell and the surface of the device to ensure the interaction between the 
cell and device; (2) the velocity of cells in the streamline to determine whether there 
is enough time to allow the bonds to form between the antibody and CD34 to retain 
the cells on the device; and (3) the shear stress that the cell is experiencing to evaluate 
whether the bond force between the cell and the surface is strong enough to overcome 
the shear forces. The range of shear stress and velocity required for the Qbend10 
(Class II CD34 Ab) and CD34 bonding to eventually capture Kg1a cells or HSCs have 
been determined in the previous experiments in Chapter 3.  
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4.3.3 Design rules: Optimization of micropost arrangement for capture efficiency  
4.3.3.1 Optimization of the microposts array: shape and spacing  
Round shape micropost was chosen over square or triangular shape ones because 
round shape micropost prevented sharp changes in the flow behavior and provided 
smooth and gradually altering shear stress profile and velocity profile, which were 
favorable in affinity-based separation where the capability to control and predict the 
flow behavior are critical in the performance of the device.  
In a given situation, when the area of the device, the dimension of the microposts, 
and the number of total and target cells in the sample are set, the spacing between the 
microposts is the key parameter that determines the enrichment performance of the 
device. Decreasing post-to-post spacing leads to more overall surface area and more 
chance of interactions between the cells and the surface of the device. However, the 
micropost design is very sensitive to clogging. Therefore the spacing cannot be 
smaller than three times of the diameter of the target cells to prevent obvious clogging 
in the device. Otherwise, when the target cells saturate the surface of the post, not 
enough room is available for the future cells to pass through. Since the diameter of the 
target cell is around 10 µm, 30 µm was used as the smallest spacing between the posts 
in all the devices. 60 µm was used as the largest spacing in those experiments with 
complicated sample conditions, which will be discussed in the following sections in 
this chapter. Since the smallest spacing used in this work was 30 µm, to maximize the 
surface area, the diameter of 30 µm was used for the microposts in all experiments in 
this work. The height of the microposts was set to be 70 µm, which was deep enough 
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to allow multiple cells to be captured in the same x, y position but different z position 
in the device. However 70 µm was not too deep to create difficulties in visualizing 
captured cells in different z planes with conventional fluorescence microscopy.   
4.3.3.2 Optimization of the arrangement of the microposts  
Once the spacing is determined, the next degree of freedom in the device design 
is the arrangement of the micropost, which influence the capture efficiency in two 
ways: (1) it largely influences the streamline and path line in the device which 
affecting how frequently the cells interact with the device; and (2) it determines the 
overall surface area available for cell capture. An equilateral triangular array design 
was proved to provide higher capture efficiency than a square array or diagonal square 
array design because it offers more surface area and distorts the streamline more 
efficiently to increase the chances of interaction between the cell and the surface.  
However, the highly symmetric arrangement of equilateral triangular array leads to 
poor capture efficiency since the cells only have the chance to interact with and be 
captured by the microposts at the beginning of device as a result of the laminar flow 
pattern in the microfluidic device, where fluid follows streamlines that are constant 
with time and do not overlap. To take advantage of its potential higher capture 
efficiency over other patterns and prevent the disadvantage related to the laminar flow 
pattern in highly symmetric array, breaking the symmetry of the array is the key.  
There are a few strategies which are designed to add different elements into the 
original arrays for this purpose. Laterally shifting the array by a distance smaller than 
the spacing every several rows has been shown to provide efficient capturing.  
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However, there are two degrees of freedom to alter in this strategy, the distance by 
which the rows are shifting and the number of rows that is shifting in the group.  
Considering the spacing and size of the target cells are the two intrinsic degrees of 
freedom in the stem cell enrichment application, this “laterally shifting rows” strategy 
does not easily provide systematic design rules to follow in deciding the optimum 
shifting distance and shifting group. An alternative strategy that applies a rotation by a 
certain number of degrees to the entire micropost array in respect to the direction of 
the flow was used in this work (Figure 4.3). In this “tilted array” strategy, the tilted 
degree in respect to the flow direction efficiently breaks the symmetry of the original 
equilateral triangular pattern, and is the only parameter to be altered in the 
optimization, which makes it possible to generate a systematic design rule with much 
less complexity in optimization. Since the symmetry of equilateral triangular 
arrangement determined that the arrays repeat their patterns every 30 degrees (six-fold 
symmetry), 0, 5, 10, 15, 20, 25, 30 tilted degrees were studied in all designs with 
different spacing and patterns.  
4.3.3.3 Optimization of array patterns to overcome clinical challenges 
The two biggest challenges in HSC enrichment from clinical blood samples are 
the big variation in the concentration of target cells in blood, varying from 0.1% to 
5%, and the big variation in the degree of clumps in blood.  Both bring huge 
difficulties and dilemmas in micropost device design. Once the titled equilateral 
triangular arrangement was chosen, the specific spacing to choose (from the 
previously determined range of 30-60 µm) is the last degree of freedom in 
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performance optimization. As discussed previously, capture efficiency, purity and 
throughput are the important parameters to evaluate the enrichment performance.  
Capture efficiency is directly influenced by the spacing of device: larger spacing leads 
to lower capture efficiency. Purity is also affected by the spacing in two ways: (1) 
larger spacing decreases the chance of clogging due to cell clumps or dense captured 
cells at the beginning of the device, thus higher purity, and (2) larger spacing 
decreases the degree of non specific binding due to decreased fabrication defects as a 
result of less etching surface as well, thus higher purity again.  Throughput is less 
affected by spacing, but still larger spacing can be tolerant to a slightly higher (10%) 
throughput without increasing velocity and shear stress to compromise the enrichment 
performance. As a result, spacing provides opposite effects on capture efficiency and 
purity/throughput (Figure 4.4A). The choice of spacing in a given condition needs to 
balance the potential of all three indicators after taking the specific requirements 
related to the clinical conditions into consideration. 
For clinical samples with low concentration (e.g., 0.1%) of target cells and free of 
clumps, a much larger sample size (50 times of the sample with 5% target cells) is 
required to process within the same time frame. Capture efficiency is the priority in 
this situation, since it helps minimize the time to acquire a large enough number of 
cells for transplantation. In this case, a device with small post spacing can solve the 
problem. 
For clinical samples with high concentration (e.g., 2-5%) of target cells and free 
of clumps, target cells can easily saturate the surface around the microposts at the 
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beginning of the device, which significantly narrow the original spacing of the device 
and largely increase the chance of clogging. In this scenario, clogging prevention 
becomes the priority in the enrichment. A large spacing is required.  Although large 
spacing help guarantee clog prevention, it also compensate the capture efficiency.  
After the target cells start to be captured at the beginning of the device, the 
concentration of the target cells decreases, clog prevention becomes less critical while 
the requirement for capture efficiency becomes more critical. As a result, a constant 
large spacing is not the optimum solution in this situation.  
Samples with high degree of clumps are even more challenging. In this situation, 
again, clog prevention is the number one priority and a large spacing is favorable.  
However, if the sample also contains very low concentration of target cells at the 
same time with high degree of clumps, it becomes extremely difficult to choose one 
spacing that ensures both clog prevention and high capture efficiency.  
To overcome the challenges due to the complexity of clinical samples, two varied 
spacing strategies were designed: an alternating pattern and a decreasing pattern 
(Figure 4.4 B&C). In the alternating pattern, the entire micropost array composed of 
two small four by four arrays of different spacing (30 and 60 µm respectively) which 
are alternating throughout the entire device. The small spacing region is responsible 
for efficient capture which the large spacing region is responsible for allowing the 
clumps to pass through without clogging the device. Each unit is only a four by four 
array to ensure the advantages of both small and large spacing regions can be 
effective. 
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In the decreasing pattern
In conclusion, it is important to acquire some basic information of the samples 
before the enrichment: the concentration of CD34 positive cells and the potential 
degree of clumps in the sample. The concentration of target cells is always reported 
after the blood sample is collected since the number of CD34 positive cells need to be 
counted during the collection process to make sure that enough number of stem cells 
is achieved for transplantation. The degree of clumps in the samples can be predicted 
according to the storage conditions as well as the sources of the sample. Cell clumps 
are found more often in frozen samples and in samples from patients of certain 
medical conditions. In autologous transplantation, patients receive their own blood for 
transplantation, which needs to be collected in advance and stored as frozen samples. 
In allogeneic transplantation, patients receive blood from HLA matched donors, 
which can be collected right before the transplantation and used when it is fresh.  
, the entire array is composed of at least two regions of 
arrays with different spacing. It starts with a large spacing region where clogging is 
minimized since the spacing is large enough to allow future cells/small clumps to pass 
through even the surface of the micropost have been completely saturated by the cells.  
In addition, the concentration of target cells is largely decreased in this region, which 
helps decrease the chance of clogging in the next region.  It continues with one or 
several regions of smaller and smaller spacing, since the chance of clogging is less 
and less and the requirement for capture efficiency becomes higher and higher.  
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Once the concentration of CD34 positive cells and the degree of clumps in the 
sample is predicted, the design rules to process complex clinical samples are as 
follows (Figure 4.4D): 
(1) If the sample conditions fall in the lower left corner, where the concentration 
of the CD34 positive cells is low and the samples are free of clump, constant small (S) 
spacing is the optimum choice to optimize the capture efficiency.  
(2) If the sample conditions fall in the upper right corner, where the concentration 
of the CD34 positive cells in high and the samples are full of clumps, constant large 
(L) spacing is the best solution to make sure clogging is minimized.  
(3) If the sample conditions reside in the lower section of the chart, where the 
clump level is really low, but the concentration of CD34 positive cells vary, 
decreasing (D) pattern starting with 60 or 50 µm spacing pattern and followed by 30 
µm spacing pattern should provide a good solution to take care of the clogging 
prevention at the beginning of the device and the high capture efficiency at the end of 
the device at the same time. 
(4) If the sample conditions are located in the left section of the chart, where the 
concentration of CD34 positive cells remains low but the degree of the clumps is 
significant, alternating (A) pattern is the solution, which help direct the cell clumps 
throughout the device while retain the high capture efficiency at the same time. 
(5) If the sample conditions are localized in the upper right region where both the 
concentration of CD34 positive cells and the degree of clumps are high, the 
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combination of decreasing and alternating patterns (A/D) could provide a decent 
solution in such really complex samples.   
4.3.3.4 Characterizing the capture efficiency from simulated results  
Capture efficiency is defined by the number of cells captured in the simulated 
region divided by the number of cells which are introduced into the simulated region 
(in a 2D model, this number is given by the dimension of the device divided by the 
diameter of the target cells.). The entire simulated region was divided into six regions, 
and the number of cells captured in each region were counted respectively and plotted 
in different colors in the column charts. As shown in Figure 4.5, the blue bar 
represented the number of cells captured in the first region in the simulated device, 
red, green, purple, blue, and orange ones for the second, third, fourth, fifth, and sixth 
region. Three patterns, constant small spacing of 30 µm (S), constant large spacing of 
50 µm (L) and alternating pattern with spacing of 30 and 60 µm (A) were modeled 
and characterized for their theoretical capture efficiency. The decreasing pattern was 
not modeled since it was the combination of the previous three thus its performance 
can be estimated based on the simulated results of the above three. The best device 
was defined as using the least numbers of color bars to reach the highest capture 
efficiency. The designs with 10, 15, 5 degree tilts were picked for small spacing, large 
spacing, and alternating pattern respectively.  
The capture efficiency of the three designs featuring different spacing patterns 
were compared by their capture efficiencies in the first region of the devices, which 
were given by the heights of the blue bars in the three selected designs, Small_10 
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pattern offered the highest capture efficiency of 60%, which was almost twice of the 
capture efficiency of Large_15 pattern (35%) and slightly higher than that of Alter_5 
pattern (55%). The data indicated that (1) spacing placed an important role in capture 
efficiency, and (2) Although the average spacing of the alternating pattern was around 
45 µm (the average of 30 and 60 µm), much larger than 30 µm and very close to 50 
µm, the capture efficiency was not compromised as much due to the efficient 
arrangement of these small spacing arrays.  
The capture efficiency of the first two regions of the device was given by adding 
the heights of both blue and red bars, giving 85% for Small_10, 59% for Large_15, 
and 76% for Alter_5. The differences in capture efficiency for the sum of the first two 
regions were not as pronounced as that for the first region only, which was due to the 
less differences in the second region, 25%, 24%, 19% for small, large and alternating 
pattern respectively. The similar performance for the second region in different 
patterns could be explained by the dilution effects, since the number of target cells 
entered into the second regions were largely varied due to the different capture 
efficiency in the first region. In order to more accurately evaluate the capture 
efficiency in the successive regions, the capture efficiencies in the successive regions 
were individually estimated by the number of cells captured in the region divided by 
the number of cells entered into the region. Figure 4.5D demonstrates the role of 
spacing in determining the capture efficiency in all successive regions. All regions 
with the small spacing pattern offered the highest capture efficiency, those with a 
large spacing pattern offered the lowest capture efficiency, and those with an 
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alternating pattern also offered relative high capture efficiency, close to what was 
observed for the case of the small spacing.  
The data also provide an estimation of the length of the device required to capture 
a given number of the cells in different patterns. Three regions were required to 
capture over 98% of cells in the small spacing and alternating patterns, however, at 
least six regions were required to capture the same amount of cells in the large 
spacing pattern, which indicated the length of the device needed to be doubled to 
capture same number of cells when switching from a small spacing or alternating 
device to a large spacing device.  
4.3.3.5 Simulation of capture efficiency for successive rounds of cells  
The static model only solved the capture events when all the cells are released at 
the same time, which did not take into consideration the dynamics of continuous cell 
release. As a result, the accumulation of captured cells in the device might alter the 
performance. To include these dynamics in the prediction of the capture efficiency, 
four successive rounds of cells were introduced into the model. Four rounds were 
chosen because the cells started to saturate the surface in small spacing pattern after 
four rounds of capture. The data indicated that the capture efficiencies of the 
individual successive round of capture as well as those of the sum of all successive 
rounds were very similar to the capture efficiencies in the first round of capture.  
Although captured cells distorted the streamlines and path lines of the flow through 
the device, the overall performance was less affected by these distortions.  Instead 
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the spacing effects and the "tilted degree" effects still dominated performance (Figure 
4.6). 
4.3.3.6 Simulation of capture efficiency in 3D models 
All the models discussed above were 2D models, which were built to model the 
center plane of the 3D device. 2D models were valid and useful for comparing the 
performance between different design patterns. However, the assumption supporting 
2D data to be good estimations of the performance of 3D devices is that the flow 
velocity and shear rate in z direction were constant. However, this assumption is not 
true in a microfluidic device with a height of 70 µm, for which the parabolic velocity 
profile in z direction will be pronounced (Figure 4.7). As a result, the actual nonlinear 
velocity profiles and shear rate profiles in the z direction render the capture efficiency 
data obtained from the 2D model not a good representation of the actual 3D 
conditions.  The parabolic profile influenced the capture events in 3 ways: (1) The 
number of cells passed different height of the device is non-linear. The number was 
peak at the central plane and decreased as it approached the bottom and ceiling. (2) 
The velocity of the cells in the same x,y position but different z position varied in the 
same way, reaching the peak in the middle plane and decreased to zero as the cells 
reached the wall. (3) So did the shear rate.  Since the capture efficiency should 
increase with decreasing velocity and shear rate, the calculated capture efficiency in 
3D should be slightly higher than the capture efficiency predicted with the 2D model.  
To characterize the capture efficiency in 3D, a simple four by four post array was 
setup similarly as the 2D model. The 70 µm-depth device was sliced into 10 planes 
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evenly, with each plane representing the flow situation in the 7 µm depth volume.  
The estimated capture efficiency was 81% for 3D comparing to 65% for 2D, so a 26% 
increase. Although the capture efficiency data in 3D model was still an estimated 
number based on several assumptions which did not reflect the conditions in real 
experiments, 3D data help evaluate how the nonlinear flow behavior in z direction in 
a device with given height influenced the capture efficiency.  
4.3.3.7 Correlation of the simulated and experimental results 
To demonstrate whether the simulated results were useful in predicting the 
experimental performance, six micropost designs were chosen for test experiments: 
Group 1 (Small_10, Large_15, Alter_5), and Group 2 (Small_25, Large_25, Alter_30). 
Group 1 consisted of the optimized design according to simulation results, while 
group 2 consisted of the least efficient designs (except for the 0 degree designs) 
according to the simulation. Figure 4.8 demonstrates that the experimental results and 
the simulated results correlated well. In both groups, the small spacing designs offered 
higher capture efficiency than the design with large spacing patterns, while the 
performance of the design with the alternating pattern was in between the two. 
Furthermore, the corresponding patterns in group 1 all outperformed those in group 2 
which indicated that the optimization of the design with respect to the best degrees of 
tilt were effective.  
4.4 Conclusions 
This chapter described the design, modeling and experimental testing of a 
silicon-based micropost device to achieve improved capture efficiency in HSC 
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enrichment. Design rules were developed to overcome potential challenges in clinical 
samples. Design optimization was performed using 2D and 3D COMSOL simulation.  
Three optimized designs were proposed and proved to be efficient in KG1a 
enrichment in cell line models that mimicked the HSC enrichment. In Chapter 5, the 
best designs identified here will be used for actual HSC enrichment experiments.   
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4.5 Figures 
 
Figure 4.1 Schematic of supporting devices for the micropost chip (upside down for 
better illustration of the structure). The PEEK manifold consists of a top piece (at the 
bottom in the figure) and a base (at the top in the figure). The top piece provides a 
glass window in the center for visualization, a thin groove outside the glass window to 
place the silicon o-ring for reversible leak-proof pressure sealing, and inlet and outlet 
ports (Red) on the side to direct the fluid. The base provides a groove to secure the 
silicon chip in place. The top and base were joined by six metal screws (Blue) on the 
side. 
  
Figure 4.2 COMSOL simulation of micropost array: Equilateral triangular post arrays 
of 100 µm diameter and 100 µm spacing. (A) Velocity profile. (B) Shear rate profile. 
(C) The distance profile: the distance from the particle to the closest surface of the 
device. (D) Particle tracing plot for capture efficiency characterization 
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Figure 4.3 Particle tracing plots for non-tilted and tilted patterns: Equilateral triangular 
post arrays of 30 µm diameter and 30 µm spacing. (A) The capture efficiency of the 0 
degree design was 45%. (B) The capture efficiency of the 25 degree design was 
100%. 
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Figure 4.4 Design principles of micropost arrangement for complicated clinical 
sample conditions. (A) Summary of the influence of spacing on capture efficiency and 
purity.  (B) Alternating pattern, scale bar represents 100 µm; (C) Decreasing pattern; 
(D) Regime map that identifies the best micropost design for different sample 
conditions encountered in the clinic.  A, S, and L stand for alternating, small spacing, 
and large spacing patterns, respectively.  S(D) stands for small, decreasing spacing 
pattern.  A(D) stands for the combination of alternating and decreasing spacing 
pattern.   
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Figure 4.5 Simulated capture efficiency of micropost design with different tilted 
degrees. (A) Small spacing design: Equilateral triangular post arrays of 30 µm 
diameter and 30 µm spacing.  (B) Large spacing design: Equilateral triangular post 
arrays of 30 µm diameter and 50 µm spacing.  (C) Alternating spacing design: 
Equilateral triangular post arrays of 30 µm diameter and 30 and 60 µm spacing.  (D) 
Relative capture efficiency in successive regions of device in the three optimized 
patterns.  (E) Particle tracing plot of equilateral triangular post arrays of 30 µm 
diameter, 30 µm spacing and 20 degree tilted. The micropost array was divided into 6 
regions, characterized by different colors corresponding to the color bars in used in 
(A), (B), and (C).    
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Figure 4.6 Simulated capture efficiency of micropost design of different tilted degrees 
at different rounds of capture: (A) Small spacing design: Equilateral triangular post 
arrays of 30 µm diameter and 30 µm spacing. (B) Large spacing design: Equilateral 
triangular post arrays of 30 µm diameter and 50 µm spacing. (C) Alternating spacing 
design: Equilateral triangular post arrays of 30 µm diameter and 30 and 60 µm 
spacing. The micropost array was divided into 6 regions, characterized by different 
colors corresponding to the color bars in used in Figure 4.5 E.     
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Figure 4.7 Flow profile and particle tracing profile in 3D model: four-by-four equilateral 
triangular post arrays of 30 µm diameter, 30 µm spacing and 50 µm height. (A) 
Scheme of parabolic hydrodynamic profile in z direction of the device. (B)  Simulated 
results of velocity field in xy plane and xz plane. (C) Particle tracing plot in 3D model. 
Red arrows indicate the flow direction. 
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Figure 4.8 Comparisons of capture efficiency in simulation and experiments. (A) 
Simulated capture efficiency of best performance group on the left and worst 
performance group on the right. (B) Experimental capture efficiency of the same two 
groups. Samples contained 0.2% KG1a cells in a mixture with HL60 cells at total 
concentration of cells of 2 x 107 cells/ml. Data represented the results of three 
replicates.   
 
 
 
 
93 
 
4.6 References  
1 Xu, Y.; Phillips, J. A.; Yan, J. L.; Li, Q. G.; Fan, Z. H.; Tan, W. H., 
Aptamer-based microfluidic device for enrichment, sorting, and detection of 
multiple cancer cells, Analytical Chemistry, 2009, 81, 7436-7442. 
2 Plouffe, B. D.; Njoka, D. N.; Harris, J.; Liao, J. H.; Horick, N. K.; Radisic, 
M.; Murthy, S. K., Peptide-mediated selective adhesion of smooth muscle and 
endothelial cells in microfluidic shear flow, Langmuir, 2007, 23, 5050-5055. 
3 Sin, A.; Murthy, S. K.; Revzin, A.; Tompkins, R. G.; Toner, M., Enrichment 
using antibody-coated microfluidic chambers in shear flow: Model mixtures of 
human lymphocytes, Biotechnology and Bioengineering, 2005, 91, 816-826. 
4 Nagrath, S.; Sequist, L. V.; Maheswaran, S.; Bell, D. W.; Irimia, D.; Ulkus, 
L.; Smith, M. R.; Kwak, E. L.; Digumarthy, S.; Muzikansky, A.; Ryan, 
P.; Balis, U. J.; Tompkins, R. G.; Haber, D. A.; Toner, M., Isolation of rare 
circulating tumour cells in cancer patients by microchip technology, Nature, 
2007, 450, 1235-U1210. 
5 Gratama, J. W.; Orfao, A.; Barnett, D.; Brando, B.; Huber, A.; Janossy, 
G.; Johnsen, H. E.; Keeney, M.; Marti, G. E.; Preijers, F.; Rothe, G.; Serke, 
S.; Sutherland, D. R.; Van der Schoot, C. E.; Schmitz, G.; Papa, S.; European 
Working Grp Clinical Cell, Anal, Flow cytometric enumeration of cd34(+) 
hematopoietic stem and progenitor cells, Cytometry, 1998, 34, 128-142. 
6 Wu, Huei-Wen; Hsu, Ruo-Chi; Lin, Chun-Che; Hwang, Shiaw-Min; Lee, 
Gwo-Bin, An integrated microfluidic system for isolation, counting, and 
sorting of hematopoietic stem cells, Biomicrofluidics, 2010, 4. 
7 Narasipura, Srinivas D.; Wojciechowski, Joel C.; Charles, Nichola; Liesveld, 
Jane L.; King, Michael R., P-selectin-coated microtube for enrichment of 
cd34(+) hematopoietic stem and progenitor cells from human bone marrow 
hematology, Clinical Chemistry, 2008, 54, 77-85. 
8 Pamme, N.; Wilhelm, C., Continuous sorting of magnetic cells via on-chip 
free-flow magnetophoresis, Lab on a Chip, 2006, 6, 974-980. 
94 
 
9 Lancaster, C.; Kokoris, A.; Nabavi, M.; Clemmens, J.; Maloney, 
P.; Capadanno, J.; Gerdes, J.; Battrell, C. F., Rare cancer cell analyzer for 
whole blood applications: Microcytometer cell counting and sorting 
subcircuits, Methods, 2005, 37, 120-127. 
10 Hu, X. Y.; Bessette, P. H.; Qian, J. R.; Meinhart, C. D.; Daugherty, P. S.; Soh, 
H. T., Marker-specific sorting of rare cells using dielectrophoresis, Proc. Natl. 
Acad. Sci. U. S. A., 2005, 102, 15757-15761. 
11 Stott, S. L.; Hsu, C. H.; Tsukrov, D. I.; Yu, M.; Miyamoto, D. T.; Waltman, B. 
A.; Rothenberg, S. M.; Shah, A. M.; Smas, M. E.; Korir, G. K.; Floyd, F. 
P.; Gilman, A. J.; Lord, J. B.; Winokur, D.; Springer, S.; Irimia, D.; Nagrath, 
S.; Sequist, L. V.; Lee, R. J.; Isselbacher, K. J.; Maheswaran, S.; Haber, D. 
A.; Toner, M., Isolation of circulating tumor cells using a 
microvortex-generating herringbone-chip, Proc. Natl. Acad. Sci. U. S. A., 2010, 
107, 18392-18397. 
12 Gleghorn, J. P.; Pratt, E. D.; Denning, D.; Liu, H.; Bander, N. H.; Tagawa, S. 
T.; Nanus, D. M.; Giannakakou, P. A.; Kirby, B. J., Capture of circulating 
tumor cells from whole blood of prostate cancer patients using geometrically 
enhanced differential immunocapture (gedi) and a prostate-specific antibody, 
Lab on a Chip, 2010, 10, 27-29. 
13 Beebe, D. J.; Mensing, G. A.; Walker, G. M., Physics and applications of 
microfluidics in biology, Annual Review of Biomedical Engineering, 2002, 4, 
261-286. 
14 Noga, S. J.; Seber, A.; Davis, J. M.; Berenson, R. J.; Vogelsang, G. B.; Braine, 
H. G.; Hess, A. D.; Marcellus, D.; Miller, C. A.; Sharkis, S. J.; Goodman, S. 
N.; Santos, G. W.; Jones, R. J., Cd34 augmentation improves allogeneic t 
cell-depleted bone marrow engraftment, J. Hematother., 1998, 7, 151-157. 
15 Welniak, L. A.; Blazar, B. R.; Murphy, W. J., in Annual review of immunology, 
Vol. 25, Annual Reviews, Palo Alto, 2007, pp. 139-170. 
16 Shpall, E. J.; Stemmer, S. M.; Johnston, C. F.; Hami, L.; Bearman, S. 
I.; Berenson, R.; Jones, R. B., Purging of autologous bone marrow for 
95 
 
transplantation: The protection and selection of the hematopoietic progenitor 
cell, J. Hematother., 1992, 1, 45-54. 
17 Copelan, E. A., Medical progress: Hematopoietic stem-cell transplantation, N. 
Engl. J. Med., 2006, 354, 1813-1826. 
18 Jansen, J.; Hanks, S.; Thompson, J. M.; Dugan, M. J.; Akard, L. P., 
Transplantation of hematopoietic stem cells from the peripheral blood, J. Cell. 
Mol. Med., 2005, 9, 37-50. 
 
 
 
  
96 
 
CHAPTER 5 
APPLICATION OF SILICON MICROPOST DEVICE:  
KG1A AND HSC ENRICHMENT  
 
 
5.1 Introduction 
The immunoaffinity based micropost design described and validated in Chapter 4 
provides the potential for high purity and high capture efficiency, but it is limited by its 
capacity to handle samples with large number of target cells due to the challenges in 
balancing the capture efficiency while trying to prevent clogging at the same time.  As a 
result, the micropost-based device is an optimum choice for rare cell separation when 
capture efficiency is the priority and the chance of clogging is low.  Blood cell 
fractionation, cancer cell isolation, and stem cell enrichment are the most popular 
examples of rare cell separation.  Blood cell fractionation refers to the isolation of certain 
type of white blood cells (roughly one to several thousands in the whole blood) [1-2], 
which are significant in diagnosis and tracking of disease progression. Studies for the 
isolation of cancer cells focus on capturing circulating tumor cells (roughly one to 109 
cells in whole blood), which are found in the blood of patients of metathesis cancers, and 
used as prognostic indicators of patient survival and tissues for genetic analyses [3-7].  
HSC enrichment (1 out of 100 to 1000 cells in red blood cell depleted blood) is critical 
for stem cell transplantation and fundamental biological studies [8-10].   
The diversity and heterogeneity of biological samples presents the biggest challenges 
in experimental analysis and separation. Cell separation techniques are usually evaluated 
and optimized in spiked cell lines and pre-diluted samples to minimize sample 
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complexity in the technology development stages. In this chapter, the previously 
developed micropost designs for HSC enrichment (Chapter 4) are tested first with spiked 
cell lines containing a low concentration of CD34 positive cells. In order to characterize 
the potential of the device to handle complex clinical samples with different 
concentrations of CD34 positive cells and different degrees of clumps, cell mixtures of 
three concentrations of target cells were tested in experiments and two different CD34 
negative cell lines with, respectively, lots of clumps and no  clumps in culture were 
chosen as model systems for possible scenarios in clinical application with ‘real’ samples.  
The three optimized device designs from simulations (Small_10, Large_15, Alter_5, see 
Chapter 4) were tested under the six sample conditions described above (2 clump 
conditions × 3 target cell concentration conditions). The optimized pattern in the clump 
free model was further tested in HSC enrichment from peripheral blood.  
5.2 Materials and Methods 
5.2.1 Micropost design patterns  
Three optimized design pattern concluded in Chapter 4 were tested in all the 
experiments.  A decreasing pattern with 25% Large_15 region at the beginning of the 
device was added to Small_10 and Alter_5 to prevent clogging. A decreasing pattern with 
50% of Large_15 and 50% of Alter_5 were tested in the most challenging sample with 
high concentration of target cells and high level of clumps.  
5.2.2 Cell lines models 
CD34 positive KG1a cells were used as models for HSC and CD34 negative HL60 
and Jurkat cells were used as models for mature white blood cells. The culture of KG1a 
and HL60 is single cell suspension, whereas Jurkat cells tend to aggregate and form small 
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clumps (around 20% of cells form clumps of roughly 4 to 10 cells) in culture.  KG1a cells 
were mixed with HL60 cells only (for clump free model) or HL60 and Jurkat cells 
together (at 1:1 ratio for 10% clump model) at three concentrations, 0.1%, 0.5% and 2% 
at a total number of cells of 2 x 107 cells/ml in PBS with 20% of sucrose to match the 
density of the medium with that of the cells.  
5.2.3 Handling of human CD34 positive cells and human peripheral blood  
Human bone marrow derived CD34 positive cells with 90% purity and viability 
(StemCell Technologies, Vancouver, Canada) were stored in liquid nitrogen upon arrival. 
The frozen vial of cells was firstly warmed in a 37 °C water bath for 2-3 minutes.  The 
cell suspension was then transferred to a 50 mL conical tube. DNase I (Sigma Aldrich) 
was added (300 μg/ml) to the cell suspension. Subsequently, 15-20 ml of 10% fetal 
bovine serum (FBS) supplemented RPMI-1640 was slowly added to the cells. The cell 
suspension was then centrifuged at 200 x g at room temperature for 15 minutes.  After the 
supernatant was removed, another 15 - 20 mL of RPMI 1640 with 10% FBS was slowly 
added to the cell pellet. The centrifugation was repeated. The cell pellets were then 
resuspended in RPMI 1640 with 10% FBS at a concentration 106 cells/ml for 
experimental analysis. Human peripheral blood, collected fresh from a donor on the day 
of experiments, was used as a source of CD34 negative cells. Red blood cells were 
removed using Histopaque-1077 (Sigma Aldrich). White blood cells were resuspended in 
10% FBS supplemented RPMI-1640 at a concentration 107 cells/ml for experimental 
analysis. CD34 positive cells and white blood cells were mixed at concentrations of 0.1%, 
0.5% and 2% with 1×107 cells per experiment in 0.5 ml of 10% FBS supplemented 
RPMI-1640.   
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5.2.4 Enrichment performance characterization  
The positive and negative cells were counted and stained with green CFDA cell 
tracing dye (Life Technologies, Grand Island, NY) and CellTrace™ calcein red-orange 
dye (Life Technologies), respectively.  The running buffer was placed in the water bath at 
37 C before each experiment. The cell suspension (0.5 ml) was loaded into a 1 mL 
syringe and was drawn into the flow chamber at the rate of 0.01 - 0.02 ml/min using 
syringe pump.  For 20-40 minutes, the cells were introduced into the device and allowed 
to interact with the CD34Ab coated microposts. The non-specific bound cells were 
detached by increasing the flow rate to 0.1 ml/min for 5 mins. Bright field and 
fluorescent images were taken after the washing steps. The microchip was then 
disassembled. The cells collected in the waste syringe and in outlet region as well as the 
remaining small amount of cells in the inlet region were collected, and concentrated for 
flow cytometry analysis.  
Purity and capture efficiency was characterized in two complementary analyses.  The 
number of positive and negative cells captured on the device was analyzed by sampling 
positions on the device with fluorescent images. The entire device was roughly divided 
into ten regions, three random spots were sampled in each region, and five photos were 
taken at different z position at each spot from the bottom to the ceiling of the device.  The 
average number of cells captured in each region was used to estimate and calculate the 
number of cells captured in the entire region. The sum of the cells captured in all ten 
regions provided an estimation of the number of positive cells and negative cells captured 
on the device, which were used to calculate the purity and capture efficiency of the 
enrichment. The number of cells that were not captured on the device, including those 
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passed the device and those did not enter the device, were counted by hemocytometer and 
analyzed by flow cytometry respectively. A million cells were processed and analyzed in 
each sample in flow cytometry. DAPI was added into each sample prior to the experiment 
to determine the viability of cells  
5.3 Results and Discussion  
5.3.1 Device design considerations 
Small spacing designs offer high capture efficiency, large spacing designs are useful 
in clog prevention, and alternating patterns are the combination of the two aiming at 
balancing the capture efficiency and clog prevention at the same time.  Since different 
sample conditions have distinct preference and priority in different aspects of the 
performance, all three arrangement patterns were optimized in simulation (Chapter 4) and 
Small_10, Large_15, and Alter_5 were chosen as the optimized arrangements patterns 
with best capture efficiency.  To maximize the advantages of the high capture efficiency 
in small spacing designs and effective clog prevention in large spacing designs, 25% of 
Large_15 were introduced into the Small_10 and Alter_5. The resulted two decreasing 
patterns (Small (D) and Alter (D)) together with the constant Large were tested in the cell 
line models and HSC enrichment experiments. Figure 5.1 shows the comparison of the 
number of cells captured in each region of the device in constant spacing designs and 
decreasing pattern designs. 0.1% of CD34 positive KG1a cells were enriched from CD34 
negative HL60 cells. The low concentration was used to prevent clogging so that the 
distribution of captured cells in different regions of the device could be compared to 
evaluate the risks of clogging in sample of much higher concentrations of target cells.  
The result indicated that the number of cells captured in the entire device was strongly 
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affected by the spacing of the device (Figure 5.1B). The number of cells captured in 
constant small spacing and alternating designs were 2.2 and 1.6 times of that in the 
constant large spacing design, which were responsible for the high risk of clogging 
especially considering the spacing of Small and Alter after the cells were captured could 
be only one third of that of Large.  However, introducing Large at the beginning of Small 
and Alter greatly reduced the risk of clogging at the beginning of the device and the 
number of cells captured at the beginning of Small and Alter region was greatly decreased 
as a result of the dilution effects in the Large region at the beginning. Although the 
capture efficiency was reduced up to 15% in the case of small spacing, the degree of 
clogging could be significantly reduced.  
5.3.2 Enrichment performance  
Characterization of enrichment performance evaluated criteria including purity, 
capture efficiency, throughput and cell viability. Throughput of the current device with an 
area of 1 cm × 1.5 cm and a depth of 70 µm was 5 × 103 cells/s, which was already 
comparable to commercial FACS, and can be easily enhanced to 105 cells/s by enlarging 
the width of the device to 5 cm and deepening the height of the device from 70 to 150 µm.  
The viability of the cells was not affected during the capture. The purity and capture 
efficiency were varied in different sample conditions (Figure 5.2).  
5.3.2.1 Enrichment performance in clump free model 
For the 0.1% KG1a samples, all three designs demonstrated very good performance 
in terms of capture efficiency (95±2%, 79±9%, 85±10% for Small (D), Large, Alter (D) ) 
and purity (75±12%, 85±7%, 82±8% for Small (D), Large, Alter (D)). The data did 
demonstrate that smaller spacing led to better capture efficiency. However, the 
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differences in capture efficiency due to spacing effects were not as pronounced as 
predicted in simulated results. This phenomenon could be explained by the fact that ultra 
low number of target cells in the sample was far away from the capture capacity of the 
device. The number of the CD34 positive cells in the 0.1% sample was only 104, which 
was much smaller than the number of cells (6 × 105) that could saturate the entire device.  
Only half of Small (D) was utilized to achieve 90% of capture, about60% of Alter (D) 
was responsible for 80% of capture, and 80% of Large was enough for 70% of capture in 
this sample conditions. The data also indicated that smaller spacing resulted in lower 
purity and large variation in purity, which was due to the higher level of surface 
roughness in small-spacing device with larger surface areas, since surface roughness 
directly increased the level of non-specific binding. In addition, the ultra low 
concentration of target cells left more than 90% of the surface available to build up non-
specific bindings, which made this spacing related non-specific binding effects more 
pronounced in low concentration samples. However, since the capture efficiency was the 
priority in samples of ultra low concentration of HSCs to minimize the time required for 
collecting enough number of cells for transplantation, Small (D) was the best solution to 
provide the highest capture efficiency and a reasonable purity.  
For the 0.5% KG1a sample, Small (D) and Alter (D) offered decent capture 
efficiency (92±4%, 81±10% for Small (D), Alter (D)) and purity (80±12%, 88±7% for 
Small (D), Alter (D)) at the same time, while the capture efficiency of Large 62±6% was 
not satisfactory although it offered a very high purity (89±5%). The purity performance 
in the three designs remained similar to that in the 0.1% sample, in that larger spacing 
offered slightly higher purity and less variation. The differences in capture efficiency 
  
103 
 
were more apparent comparing to those in 0.1% sample. A clear trend of decreasing 
capture efficiency due to increasing spacing was demonstrated. The level of capture 
efficiency in Small (D) and Alter (D) remained similar to those in 0.1% sample. However, 
larger sections of devices were required to capture 5× 104 cells in these two designs 
(roughly 80% and 100% for Small (D) and Alter (D)). The much lower capture efficiency 
of Large comparing to that in 0.1% sample was because that the number of target cells in 
0.5% sample was beyond the capture capacity of Large. Consequently, the disadvantages 
related to the spacing effects started to play a bigger role in experiment. Since both Small 
(D) and Alter (D) offered decent purity and capture efficiency but presented opposite 
preference, the choice of the design could be either of the two depending on more 
specific requirement in the actual samples.    
For the 2% KG1a samples, Large and Alter (D) offered very similar capture 
efficiency (63±10%, 82±11%) and purity (92±4%, 86±8%), while the performance of 
Small (D) was significantly deteriorated with a capture efficiency of 80±15% and a purity 
of 75±18%.  In current samples, 2× 105 cells were required to be capture, which was 20 
times of the number in 0.1% samples. Large number of target cells quickly saturated the 
surface in the beginning of the device in Small (D), where the microposts were densely 
packed with target cells. The spacing between microposts significantly decreased by 
captured cells and led to much higher chance of clogging. The 5- 20% region on the 
device could be blocked in Small (D), which explained the lower capture efficiency and 
purity as well as the large variation. Since the performance of Alter (D) was not 
significantly influenced comparing to that in 0.5% sample, the advantage of alternating 
pattern in clog prevention was proved. Since Alter (D) was the only design provided 
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consistent and reproducible performance with relative high capture efficiency and purity, 
Alter (D) was a good solution to high concentration samples free of clumps.  
In conclusion, in the clump free model in the current experimental setting (A 
micropost array of 1.5 cm by 1 cm by 70 µm was used to process samples of 1× 107 cells), 
spacing effects were dominated in the samples of low concentration (less than 0.5%) of 
target cells. Smaller spacing offered better capture efficiency without much compromise 
on the purity.  When the sample concentration increased to 2% or higher, clog prevention 
was required to be taken into consideration. Alternating patterns started to show their 
advantages in clog prevention and efficient capture at the same time. As a result, for 
sample concentrations lower than 0.5%, Small (D) could offer satisfactory performance, 
while Alter (D) could offer best performance for samples with concentrations higher than 
0.5%.  
5.3.2.2 Enrichment performance in clump model  
For the 0.1% KG1a samples in clump model with 10% cells forming clumps of 
diameter two or three times of single cells, the performance of Large and Alter (D) were 
not much affected by the presence of clump expect for the reduced reproducibility 
reflected by increased variation in both capture efficiency and purity (Figure 5.3). The 
capture efficiency was 80±15%, 82±12% for Large and Alter (D) respectively, while the 
purity were 84±6%, 82±10% respectively. Similar to the situation in 2% clump free 
samples when clogging started to create problems, the small spacing design was most 
susceptible. The performance (capture efficiency of 80±15% and purity of 75±18%) was 
largely worsened comparing to the performance in the 0.1% clump free model, which 
indicated that clog prevention was always the priority in samples with clumps even at low 
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target cell concentration, and small spacing was not a good choice in samples with 
considerable amount of clumps. The good performance of Alter (D) again proved that its 
effectiveness of clog prevention without compromising much capture efficiency. The 
slightly increased capture efficiency of Large can be explained by the increased 
interactions between cell and surface due to the disturbed flow profile by the presence of 
clumps as well as the less reproducibility of the device performance due to the presence 
of clumps.  Alter (D) was still the design of choice because it offered more consistent and 
reasonable performance.  
For the 0.5% KG1a samples in the clump model, comparing to the data from the 
0.5% clump free model, the performance of Large (capture efficiency of 67±8% and 
purity of 85±6%) was not affected, whereas the performance of Alter (D) (capture 
efficiency of 83±10% and purity of 87±12%) was slightly worsened by the presence of 
clumps, and the performance of Small (D) (capture efficiency of 60±22% and purity of 
75±18%) was further deteriorated as a result of increased level (up to 50%) of clogging.  
Similar to the situation in 0.5% clump free sample when the number of target cells was 
over the capture capacity of Large.  The spacing effects played a bigger role in affecting 
the capture efficiency of Large and Alter (D). Again, Alter (D) offered the best 
performance in sample with moderate concentration of target cells and with clumps.  
For the 2% KG1a samples in clump model, date for Small (D) was not collected 
since its performance in previous sample conditions was already worse than the other two.  
The performance of Large (capture efficiency of 62±10% and purity of 84±8%) was still 
not much affected by it. However, the performance of Alter (D) (capture efficiency of 
69±15% and purity of 70±12%) indicated that a high level of clogging started to build up, 
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deteriorating its performance. Neither of the designs provided a decent enrichment 
performance with both capture efficiency and purity reaching 80% or higher. Since the 
performance of Large was not yet affected by the increased concentration of target cells 
as well as the presence the clump, an alternative design with 50% of Large followed by 
50% Alter was proposed to reduce the built-up of clogging in alternating region by 
further diluting the target cells with more region of Large at the beginning of the device, 
at the same time guarantee the capture efficiency with the alternating pattern in the rest of 
the device. An increased performance (capture efficiency of 75±10% and purity of 
80±8%) was achieved using the adapted 50% Alter (D) design.  As a result, in really 
complex samples with high concentration of target cells and high degree of clumps, 
optimized performance could be achieved by fine tuning the spacing and the combination 
of the decreasing and alternating array patterns. 
In conclusion, in clump model with current experimental setting (Micropost array of 
1.5 cm by 1 cm by 70 µm was used to process samples of 1× 107 cells), clogging effects 
dominated in the small spacing device, which was proven to be not useful in clump 
samples despite their promise of higher capture efficiency since the capture efficiency 
was greatly reduced when clogging was present. The performance of Large was not 
affected by the presence of clumps until the concentration of the target cells reaching 2%, 
which indicated that the spacing of 50 µm was well chosen in the current experimental 
setting to provide a reasonable level of interactions between cells and the device to allow 
the clumps to pass through the device smoothly. Although Large was sufficient in clog 
prevention, its capture efficiency was not good enough.  Since alternating patterns were 
also effective in guiding the clumps through the device at relative low concentration of 
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target cells and offered better capture efficiency. The combination of decreasing and 
alternating patterns offered the solution to really complex samples for effective clog 
prevention and maximizing capture efficiency together.  
5.3.3 Capture performance in HSC enrichment 
Human bone marrow isolated HSCs were enriched from fresh peripheral blood.  
Since the chance of clogging is low in fresh blood, Small (D) and Alter (D) were chosen 
to deliver good performance since they were the designs offered better performance in 
clump free models.  The purity in all HSC enrichment experiments were better compared 
to the results obtained with the cell line models since the size of the primary HSC and 
primary blood cells were 20-40% smaller than cultured cells. The overall chances of 
interaction between surface and cells were much lower, leading to lower amount of non-
specific binding. For the same reason the capture efficiency in HSC enrichment was 
lower comparing to that in cell line models too.  Even the degree of clogging of Small (D) 
in 2% HSC sample was less. The variation in capture efficiency was slightly higher due 
to the heterogeneity of blood samples.  Since clogging was less a problem in model, the 
advantages of small spacing dominated in all the three concentrations. In all three 
concentrations, Small (D) provided capture efficiency over 75% and purity over 80%.  
5.4 Conclusions 
Three micropost designs with combinations of patterns of varied spacing were 
evaluated in experimental models.  Both KG1a and HSCs were successfully enriched at 
varied sample conditions to cover most of possible clinical situations in HSC enrichment 
for transplantation.  At least one out of the three designs was proven to offer satisfactory 
enrichment performance with high capture efficiency (>80%) and high purity (>80%) in 
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six clinical conditions in the cell line models. HSC enrichment was achieved at high 
capture efficiency up to 87% and high purity up to 80% at a throughput of 5 × 103 cells/s 
in the current testing device a throughput of 5 × 103 cells/s in the current testing device, 
which could be easily enhanced to 105 cells/s by changing the geometry of the device.  
The spacing and arrangement pattern of the devices developed here were very specific to 
overcome the challenges in HSC enrichment. However, the design rules developed in 
simulation and proved in experiments offered general principles in developing micropost 
based separation techniques for rare cell enrichment, including the choice of spacing 
relative to the size of the target cells, the choice of spacing as well as array arrangements 
to target different concentrations of cells of interests, and the solutions to overcome 
challenges due to the heterogeneity of the samples, such as big variation in cell size in the 
samples.   
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5.5 Figures 
 
Figure 5.1 Distribution of captured cells on devices of varied design patterns: 0.1% of 
CD34 positive KG1a cells were enriched from CD34 negative HL60 cells. (A) Number of 
cells captured in each individual region of the device. (B) The sum of number of cells 
captured from the beginning of the device to the current region. (C) Fluorescent images 
of KG1a cells captured on Small (D) device. (a) The beginning of Large_15 region, (b) 
Large_15 and Small_10 region, (c) The beginning of Small_10 region. (d)-(f): Small_10 
regions those were further and further away from the inlet.  
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Figure 5.2 Capture performance of KG1a enrichment in cell line models. Three device 
designs were characterized: Small (D), Large, and Alter (D). (A)-(C): Clump free model 
with different concentrations of KG1a cells. (A) 0.1%, (B) 0.5% and (C) 2%. (D)-(F): 
Clump model with different concentrations of KG1a cells. (D) 0.1%, (E) 0.5% and (F) 
2%. 
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Figure 5.3 Capture performance of HSC enrichment. 0.1%, 0.5% and 2% of human 
HSC was enriched from fresh peripheral blood in (A), (B), and (C). Two device designs 
were characterized: Small (D) and Alter (D). 
    
5.6 References  
1 Wang, Z. K.; Chin, S. Y.; Chin, C. D.; Sarik, J.; Harper, M.; Justman, J.; Sia, S. 
K., Microfluidic cd4+t-cell counting device using chemiluminescence-based 
detection, Analytical Chemistry, 2010, 82, 36-40. 
2 Sin, A.; Murthy, S. K.; Revzin, A.; Tompkins, R. G.; Toner, M., Enrichment 
using antibody-coated microfluidic chambers in shear flow: Model mixtures of 
human lymphocytes, Biotechnology and Bioengineering, 2005, 91, 816-826. 
  
112 
 
3 Gleghorn, J. P.; Pratt, E. D.; Denning, D.; Liu, H.; Bander, N. H.; Tagawa, S. 
T.; Nanus, D. M.; Giannakakou, P. A.; Kirby, B. J., Capture of circulating tumor 
cells from whole blood of prostate cancer patients using geometrically enhanced 
differential immunocapture (gedi) and a prostate-specific antibody, Lab on a Chip, 
2010, 10, 27-29. 
4 Wang, Shutao; Liu, Kan; Liu, Jian; Yu, Zeta T. F.; Xu, Xiaowen; Zhao, Libo; Lee, 
Tom; Lee, Eun Kyung; Reiss, Jean; Lee, Yi-Kuen; Chung, Leland W. K.; Huang, 
Jiaoti; Rettig, Matthew; Seligson, David; Duraiswamy, Kumaran N.; Shen, 
Clifton K. F.; Tseng, Hsian-Rong, Highly efficient capture of circulating tumor 
cells by using nanostructured silicon substrates with integrated chaotic 
micromixers, Angewandte Chemie-International Edition, 2011, 50, 3084-3088. 
5 Stott, S. L.; Hsu, C. H.; Tsukrov, D. I.; Yu, M.; Miyamoto, D. T.; Waltman, B. 
A.; Rothenberg, S. M.; Shah, A. M.; Smas, M. E.; Korir, G. K.; Floyd, F. 
P.; Gilman, A. J.; Lord, J. B.; Winokur, D.; Springer, S.; Irimia, D.; Nagrath, 
S.; Sequist, L. V.; Lee, R. J.; Isselbacher, K. J.; Maheswaran, S.; Haber, D. 
A.; Toner, M., Isolation of circulating tumor cells using a microvortex-generating 
herringbone-chip, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 18392-18397. 
6 Nagrath, S.; Sequist, L. V.; Maheswaran, S.; Bell, D. W.; Irimia, D.; Ulkus, 
L.; Smith, M. R.; Kwak, E. L.; Digumarthy, S.; Muzikansky, A.; Ryan, P.; Balis, 
U. J.; Tompkins, R. G.; Haber, D. A.; Toner, M., Isolation of rare circulating 
tumour cells in cancer patients by microchip technology, Nature, 2007, 450, 
1235-U1210. 
  
113 
 
7 Zheng, S.; Lin, H.; Liu, J. Q.; Balic, M.; Datar, R.; Cote, R. J.; Tai, Y. C., 
Membrane microfilter device for selective capture, electrolysis and genomic 
analysis of human circulating tumor cells, Journal of Chromatography A, 2007, 
1162, 154-161. 
8 Wu, Huei-Wen; Hsu, Ruo-Chi; Lin, Chun-Che; Hwang, Shiaw-Min; Lee, Gwo-
Bin, An integrated microfluidic system for isolation, counting, and sorting of 
hematopoietic stem cells, Biomicrofluidics, 2010, 4. 
9 Narasipura, Srinivas D.; Wojciechowski, Joel C.; Charles, Nichola; Liesveld, Jane 
L.; King, Michael R., P-selectin-coated microtube for enrichment of cd34(+) 
hematopoietic stem and progenitor cells from human bone marrow hematology, 
Clinical Chemistry, 2008, 54, 77-85. 
10 Huang, Y.; Yang, J.; Wang, X. B.; Becker, F. F.; Gascoyne, P. R. C., The removal 
of human breast cancer cells from hematopoietic cd34(+) stem cells by 
dielectrophoretic field-flow-fractionation, Journal of Hematotherapy & Stem Cell 
Research, 1999, 8, 481-490. 
 
 
114 
 
CHAPTER 6 
CD34 AS REACTIVE OXYGEN SPECIES SCAVENGER 
 
6.1 Introduction 
Hematopoiesis originates in the bone marrow where a rare population of 
quiescent HSCs gives rise to expanding populations of committed progenitors that 
differentiate into all of the blood cell. A balance established between these factors 
results in coexistence of quiescent HSCs, rapidly proliferating HSCs and differentiating 
HSCs in the bone marrow. The self-renewal and differentiation of HSC are regulated 
by various inhibitory and stimulating factors, such as cytokines, lipid mediators and 
bone marrow microenvironment [1-3].  
The bone marrow is a highly organized, compact tissue containing vascular 
structures [4]. Adult HSCs are predominantly located in bone marrow stroma niche, 
where the oxygen concentrations is extremely low 0.1% comparing to the average 
oxygen concentration of 4–5% in perivascular areas [5]. Several reports have 
demonstrated that hematopoiesis can be improved ex-vivo by maintaining the cell 
cultures at oxygen levels of between 1% and 3% [6-8]. Low oxygen
 
concentration 
favors the self-renewal of hematopoietic stem cells and inhibits committed progenitors, 
which corresponds to the evidence that intracellular redox potential is generally more 
reduced in proliferating cells, but more oxidized in differentiated cells. Therefore 
oxygen concentration has been recognized as an important micro-environmental factor 
for the commitment of HSCs in vitro [5, 9-10]. The regional defined hypoxic region of 
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stroma niche provides a reduced environment for HSCs to maintain their self-renewal 
ability. However, HSCs are exposed to a much higher level oxygen
 
concentration 
(higher than 10%) and dramatically increased level of reactive oxygen species (ROS) 
after they are mobilized to peripheral blood, the underlying mechanism to maintain 
HSCs in environments of higher oxygen concentration and prevent HSCs from elevated 
level of oxidative stressed were remained unclear.  
ROS such as superoxide (O2
.
) or hydrogen peroxide (H2O2) are highly reactive 
species with one or more unpaired valence shell electrons [11]. Since oxygen is 
particularly susceptible to radical formation, ROS form as a natural byproduct of the 
normal metabolism of oxygen and have important roles in many biological processes. 
The toxicity of ROS is modified by cellular enzymes that scavenge ROSs and by 
reactivity with a variety of antioxidants [12]. However, if ROS are not appropriately 
reduced in those processes, accumulated oxidative stress will result in pronounced 
cellular toxicity, such as oxidation of various cell constituents as DNA, lipids and 
proteins and consequently these oxidations may cause damage to the cellular 
machinery leading to cell death as the ultimate consequence. ROS have been 
implicated in an ever-increasing number of diseases and syndromes. These include 
various forms of non-hormone dependent cancers, atherosclerosis, ischemic 
reperfusion injury, neurodegenerative diseases, chronic inflammatory diseases, and 
some factors underlying the ageing process itself [13-17]. Besides the toxicity, ROS 
also actively participate in many biological processes, including normal cell growth, 
induction and maintenance of the transformed state, programmed cell death [16, 
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18-19] and cellular senescence [14], redox regulation of cell proliferation and 
differentiation [20-22]. The regulation of oxidative stress has been shown to be 
necessary for the maintenance of the capacity of HSCs to self-renew, which indicates 
that antioxidants may present on HSCs to prevent them from the attacks of ROS.   
Similar to the interests in the hypoxia environments of HSCs and the maintenance 
of HSCs during their circulation in normoxia environments in peripheral blood, many 
studies have been investigating the hypoxia state in pathological conditions in 
metastatic solid tumor and the adaptation of the circulating cancer cells during their 
circulation in normoxia environments in blood [13]. The noncycling primary tumor 
cells exist at a limiting distance of 100–150 μm away from blood vessels, where the 
oxygen concentration is low. However as the cancer develops into metastatic stages, 
metastatic tumor cells circulate through the bloodstream after emigrating from the 
primary tumor until they launch a new tissue [23-24]. Again, the mechanism allowing 
the circulating tumor cells to survive in environments of dramatically different 
oxygen levels is unknown. Although cells are known to sense the oxygen level and 
accordingly regulate a number of genes to adapt them to the changing environment, 
the regulation required to cope with the changes between two significantly different 
oxygen levels might involve additional mechanisms. We hypothesized that the two 
stories might share similar functional components such as similar antioxidants. The 
coincidence of the up-regulation of mucin proteins when cancer cells become 
metastatic  [25-26] and the preferential expression of sialomucin CD34 on 
proliferating HSCs in peripheral blood but not on quiescent HSCs in bone marrow 
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niche or mature blood cells indicated the potential that CD34 may serve as 
antioxidants in activated HSCs in peripheral blood with high oxygen tension [27-28].  
Mucin domains are common to a wide range of extracellular and trans-membrane 
proteins including mucin, sialomucins (to which CD34 belongs), and lectin 
ligands [29-30]. The CD34 molecule is a monomeric type I integral trans-membrane 
glycoprotein
 
(Figure 6.1). The 373 amino-acid protein backbone (40 kDa) is heavily 
glycosylated with a maximum of 9 complex-type N-glycans, numerous highly 
sialylated O-linked glycans and a cysteine rich region with six cysteines [31]. This 
glycosylation pattern is characteristic of the sialomucin family. The function of the 
CD34 antigen in early hematopoiesis still remains elusive. The mucin-like structure of 
CD34 suggests a role in cellular adhesion, possibly in adhesion of progenitors and 
stem cells to the stromal cells [27]. The gain of CD34 expression after HSCs are 
mobilized from bone marrow to peripheral blood and the loss of CD34 expression 
after differentiation on HSCs indicate that CD34 might be necessary for the functions 
of HSCs, i.e. their self-renewal capacity as well as their favor of reduced state [6-8, 
32-36]. The structure of CD34 does suggest its potential as an antioxidant. The six 
cysteines at extracellular domain right after trans-membrane domain offer a great 
reductive force when meeting with oxygen and other oxidative species [37-38]. Thiol 
groups on cysteines offer high reductive potential, which are very reactive in 
quenching the unpaired electrons in ROS to release oxidative stresses. The thiols are 
then oxidized to sulfenic acid, disulfide bond, sulfinic acid or sulfonic acid depending 
on the level of oxidative stress. For those cysteines that are present in the form of 
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disulfide bonds, which are responsible to maintain the secondary structure of the 
protein, still have the potential to reduce ROS. On the other hand, sialic acids, which 
are abundant as the terminal sugar of sialoglycoprotein and sialoglycolipids, have 
high reductive potential as well. Reactions between sialic acid and different reactive 
oxygen species have been reported. A recent report indicated that the sialic acid on the 
terminal position in mucin could react with hydrogen peroxide under physiological 
conditions (Figure 6.2) [26, 39]. The high reductive potential of cysteines and sialic 
acids provides supporting information for the hypothesis that CD34 is an antioxidant 
to protect HSCs from oxidative stress. 
In this chapter, the hypothesis of CD34 as ROS scavenger in activated HSCs will 
be discussed and tested. Cultured cell lines with and without CD34 expression were 
developed by transfection. Hydrogen peroxide was used to induce apoptosis in both 
CD34 positive and negative cell lines, the level of induced apoptosis was analyzed by 
flow cytometry. Preliminary data demonstrated that CD34 positive cells were less 
susceptible in hydrogen peroxide treatment as compared to CD34 negative cells. 
6.2 Materials and Methods 
6.2.1 Establish stably transfected CD34+ cell lines 
KG1a cells were counted, washed, pelleted, and stored in lysis buffer at −80°C 
before extraction. Total RNA was extracted from 5 × 106 KG1a cells with Oligotex 
Direct mRNA Mini Kit (Qiagen, Valencia, CA). mRNAs were reverse transcribed 
following the instructions of the First Strand cDNA Synthesis Kit for RT-PCR. The 
forward pirmer was 5′- ATGCTGGTCCGCAGGG -3′, the reverse primer was 5′- 
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GAGCTGGAACCCTGA -3’. cDNA of CD34 was cloned into mammalian 
expression vector pcDNA3.1+ for transfection. Stably transfected CD34+ cell lines in 
both CHO cells were established by using Lipofectamine transfection followed by 
four week selection in 800 µM of antibiotic G-418 sulfate. The CD34 expression level 
in transfected cells was analyzed by flow cytometry. Transfected cells were washed, 
resuspended at 1 × 106 cells/mL in PBS containing 0.1% bovine serum albumin BSA, 
and incubated with 20 μg/mL anti-CD34 (Qbend10, class II) at 4°C for 30 minutes. 
After washing, cells were resuspended at 1 × 106 cells/mL and separated by a 
FACScan (Becton Dickinson). Highly positive CD34 cells were sorted and cultured 
individually to develop a stable cell line (CD34++) with high level of CD34 
expression, which is ideal for relating cell responses in different biological treatments 
to the presence of CD34 on the cell surface, when using the wild type CD34- cell as a 
negative control.  
6.2.2 Cell culture and hydrogen peroxide treatment  
KG1a was cultured in RPMI 1640 medium containing 10% FBS. CHO and 
HEK293 cells were cultured in DMEM supplemented with 10% FBS. CD34+ and 
CD34- CHO cells were seeded at 1.5×105cells/well in standard 6 well plates for 12 hrs. 
CHO cells were then treated with H2O2 (800 μM, Sigma Aldrich, St Louis, MO) for 24 
hrs to induce apoptosis.  
6.2.3 Flow cytometry analysis   
CD34 expression in both samples were analyzed by flow cytometry by staining 
cells at the concentration of  1 × 106 cells/ml with 20 μg/mL PE conjugated 
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anti-CD34 (Qbend10, class II, Invitrogen, Grand Island, NY) at 4°C for 30 minutes. 
Cells were checked for apoptosis and necrosis by staining every 0.3 ml of cell 
suspension at 1 × 106 cells/ml with 10-20 μl of Annexin–Alexa647 (Invitrogen, Grand 
Island, NY)  [40] and 5 μl of DAPI/ PI (Invitrogen, Grand Island, NY) prior to the 
flow cytometry analysis. Data were analyzed statistically by ANOVA and a p-value 
less than 0.05 was considered significantly different. 
6.3 Results and Discussion 
6.3.1 Hydrogen peroxide induced apoptosis  
Moderately elevated concentrations of ROS are found to induce apoptosis, which 
is a programmed cell death naturelly occurring in contrast to necrosis, an unnatural 
death of cells caused by external factors. Hydrogen peroxide induced apoptosis were 
studied in CD34 presenting cells to investigate whether CD34 protects cells from 
ROS. Hydrogen peroxide induced apoptosis assay was designed based on annexin, a 
phospholipid-binding protein with high affinity to phosphatidylserine, which is 
translocated from the inner to the outer leaflet of the plasma membrane in apoptotic 
cells. Both apoptosis and necrosis were characterized in the hydrogen peroxide 
treatment to evaluate the damage due to ROS as well as separating the damaging 
mechanism related to ROS from the others.  
6.3.2 Factors influence hydrogen peroxide induced apoptosis  
Forty percent killing concentration of hydrogen peroxide was defined as the 
concentration at which 40% of apoptosis and necrosis were induced in wild type CHO 
cells. Since the hypothesis was that CD34 presenting cells survived better under same 
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treatment than CD34 negative wild type cells, the concentration of hydrogen peroxide 
leads to 40% killing in wild type CHOs leaves enough room for a higher survival rate 
for CD34 presenting cells. Apoptosis was regulated and influenced by many factors 
including cell media, the length of the treatment, cell cycles, and seeding conditions. 
Both serum free media and media supplemented with 10% FBS were studied. No 
significant differences were observed between the two media conditions for 24 hrs of 
treatment. FBS containing media was chosen in the actual experiments. Hydrogen 
peroxide treatment for CHO cells were monitored after 0, 4, 8, 12, 24, 48 hrs at the 
concentration of hydrogen peroxide of 800 μM. Morphology changes due to apoptosis 
could be observed after 12 hrs of treatment, and progressed gradually in the next 12 
hrs, when the sign of necrosis started to appear. 24 hrs of treatment was chosen since 
apoptosis was dominating in the first 24 hrs of treatment. Cell cycle was synchronized 
by seeding the cells for 12 hrs prior to the treatment. Three seeding concentrations 
were tested 5 x 104cells/well, 1 x 105
 
cells/well, 1.5 x 105
 
cells/well in standard six 
well plates. [Figure 6.3] No sign of apoptosis was observed at the highest seeding 
density, 38% of apoptosis was demonstrated at the intermediate seeding density and 
over 67% of apoptosis was shown at the lowest seeding density. The intermediate 
seeding density was chosen. As a result, 40% of killing of wild type CHO cells was 
achieved hydrogen peroxide treatment at the concentration of 800 µM for 24 hrs.  
6.3.3 Hydrogen peroxide induced apoptosis vs. CD34 expression in CHO 
In order to relate the expression of CD34 to H2O2 induced apoptotic death in cells, 
CD34 transfected CHO were sorted based on their expression level of CD34 into two 
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cell lines, expressing high (CD34++) or low level (CD34+) of CD34 respectively. 
Viabilities among different subgroups (wild type CD34-, CD34+, and CD34++) were 
significantly different (Figure 6.4). The viability in CD34++ population was much 
greater than that in CD34+ or CD34- populations. This observation indicated CD34 
did protect cells from ROS induced apoptosis, supporting the hypothesis that CD34 
serves as a ROS scavenger for HSCs.   
6.3.4 Future work 
6.3.4.1 Molecular basis for CD34 as ROS scavenger  
CD34 was proved to protect cells from hydrogen peroxide induced apoptosis. 
Since there are two known antioxidant motifs on CD34 which might be the reason 
why it can fight against ROS, the next step is to investigate the molecular basis for the 
protection from CD34. Developing cysteine mutated CD34+ cells will help elucidate 
whether the six cysteines on CD34 contribute to this antioxidant protection. Altering 
the side chain glycosylation on CD34 will help understand the function of sialic acids 
as an antioxidant in CD34. The data from there will lead to the answer whether CD34 
is a ROS scavenger in HSCs and possible molecular bases for this function.  
6.3.4.2 CD34 FL and CD34 TF Expression under Hypoxia.  
The CD34 gene is transcribed into two alternatively spliced mRNAs that encode 
full length (CD34FL) or truncated forms (CD34TF) of CD34 cell surface antigen. 
These transcripts differ by the presence of an additional exon, exon x, between exon 7 
and exon 8 in the truncated form (Figure 6.1C). Exon x contains a premature stop 
codon that ends translation before the intracellular signaling domain is transcribed. 
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The CD34FL and the CD34TF transcripts encode identical extracellular and 
transmembrane domains but differ in cytoplasmic domains of 73 and 16 amino acids, 
respectively. Several studies indicated that the two CD34 forms played different roles 
in the biology of CD34+ cells [41-42]. Since both transcripts share the extracellular 
domain, where the two potential antioxidant sites are located, the survival of CD34FL 
and CD34TF presenting cells under ROS induced apoptosis will be at the same level 
unless the cytoplasmic domain offered additional mechanism to cope with oxidative 
stresses. Investigation of both transcripts in different oxygen levels would provide 
insights into the importance of its extracellular versus cytoplasmic domains in 
response to the changing oxidative stress. 
 
Hypoxia induced changes of mRNA level of CD34FL and CD34TF can be 
investigated to test the contribution of extracellular versus cytoplasmic domains in 
CD34 as a ROS scavenger [6-8, 34-36]. KG1a cells will be used as a hematopoietic 
stem cell model to work out the experimental protocol including the appropriate 
primer sets and the housekeeping genes. The effects of short term (24 h) culture in 
hypoxia (1% O2) compared to normoxia (20% O2) on the expression of full length and 
truncated form of CD34 transcripts and on the expression of the CD34 antigen will be 
studied by q-PCR and flow cytometry, respectively. The protocol will then be applied 
to the CD34+ human blood cells to investigate the possible relationship between the 
expression levels of the two transcripts and the preservation of “stemness” from 
oxidative stress in HSCs. The relative expression levels of the two transcripts in 
different oxygen environments will provide insights on the role of extracellular 
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domain, where two antioxidant sites locate, in response to the oxidative stress, which 
could provide supporting information to our hypothesis.  
6.4 Conclusions 
Our hypothesis that CD34 has the potential to act as a free radical scavenger to 
help maintain the “stemness” of HSCs under increasing oxidative stress was tested. 
Preliminary results indicated that CD34 protects CD34 presenting CHO cells from 
apoptosis induced by hydrogen peroxide. Further experiments could elucidate the 
molecular basis and mechanism of the role of CD34 as ROS scavenger.  This study 
could lead to the discovery of new function of CD34 and other similar sialomucin 
proteins, new understandings in stem cell biology for the maintenance of HSCs in 
circulating blood, and new hints in discovering the disease mechanism that helps 
circulating tumor cells to adapt to dramatically increased oxygen concentration when 
they migrate from their primary site into blood stream. A deeper understanding of this 
biological question related to metastasis could help develop therapeutic strategies to 
fight spreading of cancer to form secondary tumors elsewhere in the body.     
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6.5 Figures 
 
Figure 6.1. Schematic of CD34. A: Schematic of CD34 structures. CD34 has an 
extensively O-glycosylated (horizontal lines) and sialylated (horizontal lines with 
arrowheads) serine-, threonine- and proline-rich extracellular mucin domain (green), 
sites of N-glycosylation (lines with circles), and a cysteine-containing globular domain 
(dark blue). The transmembrane domain (light blue) is followed by short cytoplasmic 
tails (red) containing putative phosphorylation sites. B: Schematic representation of 
structural features of CD34. C: Alternative splicing. CD34 display patterns of 
alternative splicing, and can exist as truncated versions that lack most of the 
cytoplasmic tail. Figure A, C were reprinted from  [31], copyright 2008, The Company 
of Biologists. Figure B was reprinted from  [43], copyright 1994, The Society for 
Applied Immunohistochemistry 
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Figure 6.2 Reaction scheme showing how N-acetylneuraminic acid(NANA) is 
oxidized by an equimolar amount of H2O2 to provide its decarboxylated product, 
4-(acetylamino)-2,4-dideoxy -D-glycero-D-galacto-octonicacid(ADOA). Figure was 
reprinted from  [39], copyright 2007, Elsevier. 
 
 
 
Figure 6.3 Hydrogen peroxide induced apoptosis in CHO at different seeding 
conditions. (A)-(C): Untreated wild type CHO cells were seeded after 36 hrs. (D)-(F): 
Wild type CHO cells were treated with 800 µM of hydrogen peroxide for 24 hrs after 
12 hrs of seeding. Three seeding densities were tested: 5 x 104cells/well, 1 x 105
 
cells/well, 1.5 x 105
 
cells/well.      
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Figure 6.4. Cell viability assay coupled with CD34 staining to investigate the CD34 vs. 
ROS induced apoptosis. (A): PI and Annexin-Alexa647 staining was used to 
distinguish live, apoptotic and necrotic populations. (B): Qbend10-PE staining was 
used to characterize CD34 expression. (C): Compare viabilities in population with 
different CD34 level.  
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